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Abstract 
Pygopus is a recently discovered downstream component of the Wnt signaling 
pathway required for ll- cateninff cf dependent transcription. It has been proposed to act 
as a downstream mediator of transcription through its indirect intemction with jl-catenin. 
Misactivation ofWnt signaling resulting in the overexpression of mitogenic Wnt target 
genes has been implicated in the progression of human cancer. In fact, abermnt Wnt 
signaling has been hypothesized to contribute to tbe formation of breast tumours. 
However, there are limited studies that conclusively address this question. Therefore, the 
purpose ofthis study was to examine tbe expression and requirement of the newly 
discovered Wnt signaling component Human Pygopus 2 (hPygo2) in this malignancy. 
To assess the expression ofhPygo2 in malignant breast cancer cell lines and 
tumours, I characterized antiserum which specifically recognized hPygo2 protein. 
hPygo2 was found overexpressed in the nuclei of breast tumour cells and tissue but not in 
nonnal breast cells and tissue. Knockdown studies using siRNA or antisense 
ol igonucleotides has demonstrated that bPygo2, but not jl-catenin, was required for the 
growth ofMCF-7 and MDA-MB-468 breast cancer cell lines and expression of the Wnt 
target gene Cyc/in Dl. Furthermore, I found that Pygopus I but not Pygopus 2 was 
required for mediating the Wnt signal through the key mediator,jl-catenin. These novel 
observations suggest that the requirement for nuclear overexpression of hPygo2 can be 
independent ofWnt/ll-catenin in the growth of breast carcinoma cells. Therefore, 
hPygo2 may be a more suitable therapeutic target tban elements of the canonical Wnt 
pathway for the treatment of breast cancer. 
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CHAPTER I 
INTRODUCTION 
1.1 Signal Transduction and Cancer 
Chapter 1: Introduction 
Signal transduction is a complex process that involves the relaying of messages 
from outside of the cell, into the cell and ultimately to specific target proteins that can 
mediate cellular responses. Signaling can be initiated by extracellular molecules known 
as ligands, or by mechanical stresses encountered by the cell. The signal or message is 
transduced from the outside of the cell into the cell by the activation or repression of 
specific intracellular signaling proteins. Inside the cell, further downstream proteins 
initiate the activation of specific target proteins which can mediate a number of cellular 
processes, such as: cell metabolism, cell morphology, cell migration, facilitative transport 
of ions and proteins, gene expression, and so on. Therefore, signal transduction is a 
mechanism for cells to respond to and interact with their environment. 
Signal transduction processes that ultimately result in proliferation, differentiation 
and survival are often mediated by extracellular messengers known as growth factors or 
mitogens. The binding of growth factors to their respective cell surface receptors results 
in the activation or repression of intracellular signal transduction cascades involved in the 
control of cell numbers. Activation or repression of signal transduction pathways that 
increase cell proliferation rates and promote cell survival are therefore important for the 
normal growth and development of an organism. On the other hand, aberrant activation 
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or repression of the same signaling pathways may cause the uncontrolled growth and 
proliferation of cells, which may result in cancer. 
The loss of the ability for a cell or clone of cells to properly regulate cell 
growth and division is one hallmark of cancer. Genetic mutations leading to uncontrolled 
cell growth can arise from a number of different signaling pathways (Vogelstein and 
Kinzler, 2004). Gain-of-function mutations can occur in signaling pathways that result in 
the overexpression of proteins involved in the promotion of cell growth. For example, 
activation of the oncogene c-myc through gain-of-function mutations, has been 
implicated in the progression of human cancer (Pelengaris and Khan, 2003). On the other 
hand, loss-of-function mutations can occur in signaling pathways that result in the 
underexpression of proteins which may act to promote the regular death and turnover of 
cells. For example, inactivation of the tumour suppressor Adenomatous Polyposis Coli 
(APC), through loss-of-function mutation has been identified as being a cause for familial 
adenomatous polyposis (F earnhead et a/., 200 I). 
In the context of cancer, it is clearly very important to understand the molecular 
mechanism of how signal transduction occurs and to identiJY mutations that lead to 
uncontrolled cell proliferation. Such knowledge is required to develop molecular and 
biological based treatments and therapies. My work presented in this thesis will 
concentrate on a newly discovered protein of the Wnt signal transduction pathway, 
known as Pygopus, and the possible role that it may play in cancer. 
2 
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1.2 The Wnt Signal Transduction Pathway 
The central role ofWnt signaling is to promote normal cell proliferation and cell 
migration in embryogenesis (Cadigan and Nusse, 1997) and in stem cell proliferation in 
adults (Willert eta/., 2003). Since Wnt proteins promote the growth of cells, they can be 
regarded as growth factors. The Wnt signal transduction pathway is very complex. For 
example, in humans, there have been 19 Wnt ligands that have been identified and each 
one likely mediates a different cellular response. In the following sections, I will 
concentrate on the classical canonical and non-canonical Wnt signaling pathways, as well 
as the newly discovered protein Pygopus and its role in the canonical Wnt signaling 
pathway. The regulation of the Wnt pathway is controlled at multiple levels but it is 
important to remember that Wnt signaling can also be regulated by many different 
proteins that are intermediates of other cell signal transduction pathways. Together, the 
cell must carefully orchestrate a variety of signals along with the Wnt signal in the 
normal growth and development of an organism. 
1.2.1 Canonical Wnt Signaling 
The canonical Wnt signaling pathway refers to the first discovered and most well 
known signaling pathway mediated by Wnt ligands. It involves the activation of the 
intracellular signaling intermediate J3--a~tenin and its subsequent transcriptional 
regulation of Wnt responsive genes. J3--eatenin was originally identified as a bridging 
molecule that links E-Cadherin and Actin to mediate cell to cell adhesion (Wheelock and 
Knudsen, 1991). Since then, it has been found that J3--eatenin is a key mediator ofWnt 
3 
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signaling, acting downstream of the ligand receptor complex (Peifer eta/., 1993). In the 
event of a Wnt signal, ~-catenin becomes activated and translocates to the nucleus to 
activate gene transcription. The critical function of Wnt signaling is to regulate the 
normal growth and proliferation of cells that form complex tissues. Consistent with its 
role in promoting tissue growth, the canonical Wnt signaling pathway positively regulates 
genes involved in cell growth and proliferation, such as Cyclin Dl (Tetsu and 
McCormick, 1999; Shtutrnan eta/., 1999) and c-myc (He eta/., 1998). Therefore, the cell 
must carefully regulate this signaling pathway in the absence of a Wnt ligand to control 
its growth and proliferation. 
In the absence of a Wnt signal or ligand, the pathway is negatively regulated in 
order to keep it in an inactive or "off" state (Figure 1.1). The binding ofWnt to its 
receptor causes a derepression of the pathway which attenuates the constiMive 
degradation of cytoplasmic [3-catenin allowing it to accumulate in the nucleus where it 
displaces (or replaces) transcriptional repressors ofWnt target genes. 
The repression of the Wnt pathway in the absence of signaling has been well-
documented and can occur at many levels in the pathway. At the cell membrane level, the 
cytoplasmic Wnt protein Dishevelled (Dsh), which is normally activated by the active 
Frizzled receptor/Wnt ligand complex, can be repressed by a number of proteins. For 
example, Frodo/Dapper (Dap) proteins have been shown to bind to Dsh and inhibit its 
binding to Frizzled (Cheyette eta/., 2002; Wong eta/., 2003). Naked has also been 
shown to bind to Dsh, thereby acting as antagonists of Wnt signaling (Roussel eta/., 
2001; Wharton, Jr. eta/., 2001). 
4 
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Figure 1.1 Regulation of jl-catenin in the absence of a Wnt sigual. In the absence of 
a Wnt signal, nuclear and cytoplasmic 13--<:atenin is recruited by APC, resulting in the 
assembly of the !3--<:atenin destruction complex, consisting of Axin, APC and GSK313. 
Specific N-terminal residues ofl3--<:atenin are phosphorylated by GSK313, targeting it for 
ubiqitination by 13-TrCP and subsequent degradation by the 26S proteasome. Wnt target 
genes are repressed by interacting complexes ofTCF/LEF, Groucho (Grg) and HDAC 
proteins. 
Degradation 
--
----
--
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The inhibition or inactivation of Dsh ultimately results in the destruction of free 
cytoplasmic/nuclear 13-catenin. 13-catenin turnover is promoted by a protein known as 
APC, an intracellular scaffolding protein, which binds to free 13-catenin in the cytoplasm 
and the nucleus resulting in its nuclear export (Henderson, 2000; Neufeld eta/., 2000). 
APC acts as a trap for free 13-catenin and initiates its degradation by recruiting it to a 
multi protein destruction complex, which includes: Axin and Glycogen Synthase Kinase 
313 (GSK313) (Hart eta/., 1998). Assembly of the 13-catenin destruction complex is 
essential for the phosphorylation of 13--<:atenin mediated by GSK313 (Ikeda eta/., 1998). 
The phosphorylation at specific N-terminal residues marks !3-catenin for ubiquitination 
by the E3 ubiquitin ligase, 13-Transducin repeat-Containing Protein (13-TrCP), therefore 
targeting it for proteasomal degradation (Hart eta/., 1999). 
In the nucleus, the expression ofWnt target genes are repressed by a complex 
including T-Cell Factor/Lymphoid Enhancing Factor (TCF/LEF), whose function is to 
bind to specific consensus sequences at the promoters ofWnt genes, and the 
transcriptional repressor Groucho ( Grg) (Roose et a/., 1998; Cavallo et a/., 1998). The 
interaction between TCF and Grg recruits chromatin remodelling proteins, such as 
Histone Deacetylase (HDAC) to Wnt target genes resulting in the deacetylation of nearby 
Histones. This event results in the local condensation of chromatin and therefore, the 
repression ofWnt target genes (Chen eta/., 1999). 
!3--<:atenin activity can also be negatively regulated by a number of other proteins. 
For example, Inhibitor of 13-catenin (I CAT) (Tago eta/., 2000), as well as a protein 
known as Teashirt (Gallet eta/., 1999; Waltzer eta/., 2001) are among the few proteins 
6 
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that bind to and regulate (3-catenin turnover, and hence its transcriptional activity by 
promoting its degradation. 
Activation ofWnt signaling requires the presence of a Wnt ligand (Figure L2). 
Secreted Wnt ligands bind to seven pass transmembrane receptors, known as Frizzleds 
(Bhanot eta/., 1996). The activation ofWnt signaling is dependent on tbe ability of tbe 
Frizzled receptor to recruit transmembrane proteins of the low-density lipoprotein family, 
Low-density Lipoprotein Related Protein 5/6 (LRP5/6) upon Wnt ligand binding (Wehrli 
eta/., 2000; Tarnai eta/., 2000). This assembly oftbe Wnt activation complex is 
necessary for tbe initiation of signal transduction and results in activation or derepression 
of the cytoplasmic signaling intermediate Dsh, by an unknown mechanism (Klingensmith 
et al., 1994; Yanagawa eta/., 1995). At this point, the Wnt message can be transduced to 
either tbe canonical Wnt signaling pathway, or to the non-canonical Wnt signaling 
pathways (reviewed in section 1.2.2). 
In the context of canonical Wnt signaling, Dsh phosphorylation and activation can 
be mediated by a number of otber proteins including Casein Kinase I (CKI) (Peters eta/., 
1999) and Casein Kinase 2 (CK2) (Willert eta/., 1997). Dsh activation ultimately results 
in tbe inhibition of(3-catenin phosphorylation mediated by tbe Axin/APC/GSK3f3 
complex (Kishida et al., 1999). More specifically, tbe interaction ofDsh witb Axin and 
Fratl promotes the dissociation of Axin and GSK3f3 (Li eta/., 1999). By escaping 
GSK3f3 mediated N-terminal phosphorylation, (3-catenin is stabilized and accumulates in 
the cytoplasm. At this point, (3-catenin stability is further enhanced by tbe 
7 
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Figure 1.2 Activation ofthe classical canonical Wnt signaling pathway. Wnt ligands 
bind to Frizzled transmembrane receptors to activate Dishevelled which, in turn, inhibits 
the formation of the ~tenin destruction complex, responsible for the phosphorylation 
of ~-catenin. ~-catenin accumulates in the cytoplasm and is free to translocate into the 
nucleus to activate transcription. Nuclear ~tenin forms a complex with TCFILEF, 
CBP, Bcl-9 and Pygo. This complex interacts with the general transcriptional machinery, 
which is necessary for the transcription of Wnt target genes. 
====:::::::::::::::::::::::::: Cell membrane 
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phosphorylation of specific residues distinct from the phosphorylation sites of GSK3J3, 
which is mediated by CK2 (Song et a/., 2003 ). 
The stabilization of j3--catenin, results in its accumulation in the cytoplasm. 
Subsequently, it can translocate to the nucleus where it interacts with specific nuclear 
proteins to form an active transcriptional complex. The transcriptionally active 
j3.,;atenin complex includes many other proteins. TCF/IEF directly binds to 
Deoxyribonucleic Acid (DNA) enhancer sequences at the sites ofWnt target gene 
promoters (van De et a/., 1997), thought to occur by a mechanism that includes the 
displacement ofGrgffCF co-repressor complexes. Chromatin remodelling factors, such 
as the cAMP Responsive Element Binding Protein (CREB) Binding Protein (CBP) play a 
role in the transcription of target genes by acetylating nearby histone proteins, resulting in 
the decondensation of DNA to allow TCF/j3--catenin complexes and the general 
transcription machinery to gain access to the Wnt target gene promoter (Waltzer and 
Bienz, 1998; Takemaru and Moon, 2000) The recently discovered proteins, B-Cell 
Lymphoma-9/Legless (Bcl-9) and Pygopus (Pygo ), have been shown to be involved in 
the transcription ofWnt target genes. The exact role ofBcl-9 and Pygo in promoting Wnt 
dependent gene activation is currently unknown, although they have been proposed to 
play a role in chromatin remodelling as well, allowing access ofTCF/j3.,;atenin to the 
promoters of Wnt target genes (Kramps eta/. , 2002). 
9 
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1.2.2 Pygopus, a Novel Component ofthe Wnt Signaling Pathway 
As briefly mentioned in section 1.2.1, Pygopus is a novel component of Wnt 
signaling proposed to be required for Wnt dependent transcription. Pygopus was 
originally discovered in Drosophila by yeast two-hybrid analysis of proteins that were 
able to interact with another novel Wingless (Wg)/Wnt component, Legless/Bcl-9 
(Kramps eta/., 2002). Pygopus was also discovered by another group by a genetic screen 
of suppressors of an activated Armadillo (Drosophila 13-<:atenin homologue) phenotype 
in the Drosophila eye (Thompson eta/., 2002). The name "Pygopus" is also the name of 
a class oflegless lizards with scaly skin found in Australia. It was used to describe the 
phenotype of mutant Pygo flies, which lacked legs and antennae. Pygo mutants were 
strikingly similar to other Wg signaling mutants, which lead both groups to believe that 
Pygopus might be involved in transducing the Wg signal. Further characterization of 
Pygo revealed that it was indeed a component ofWg signaling in Drosophila. Mutants of 
Pygo were able to suppress direct Wg target genes, such as Ultrabithorax Band Distal-
less. In the Kao lab, Xenopus Pygopus was initially discovered to be involved in neural 
patterning.(Lake and Kao, 2003). Since then, Xenopus Pygopus has been shown to be 
required for body axis formation (Belenkaya eta/., 2002). Finally, in human colorectal 
carcinoma cells, Pygo was shown to be required for TCF-dependent transcription 
(Thompson et a/., 2002; Kramps et a/., 2002). Therefore, there is much evidence 
implicating a role for Pygopus proteins in vertebrates, as in Drosophila, as downstream 
mediators ofWnt signaling. 
Pygopus proteins (Figure 1.3) in general, are rich in proline and glycine residues 
and share several conserved amino acid sequences. At theN-terminus, there are two 
10 
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Figure 1.3 Structure and conserved domains of Pygopus proteins. Pygopus proteins 
from Drosophila ( dPygo ), Xenopus (Xpygo) and human (hPygo) share several conserved 
domains. At the C-terminus, Pygo family members share a conserved PliD domain, 
responsible for the protein-protein interaction with Bcl-9. At theN-terminus, Pygo family 
members share two conserved protein motifs. The NLS is responsible for mediating the 
nuclear localization ofPygo proteins. The NliD domain shares no homology to any 
known protein motifs. The NliD is conserved amongst Pygo protein family members and 
is hypothesized to be required for the activation ofWnt-dependent transcription. 
dPygo 
hPygo1 
~ - -
hPygo2 I·-
0 -Non-conserved 
· -NLS 
·-NHD 
· -PHD 
815aa 
389aa 
368aa 
419aa 
406aa 
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conserved amino acid sequences present in all known Pygo family members: a nuclear 
localization sequence (NLS), as well as a conserved sequence known as theN-terminal 
Homology Domain (NHD) (Thompson eta/., 2002; Kramps eta/., 2002). The NHD 
shows no sequence similarity to any known protein domains or conserved sequences. The 
proposed function of the NHD domain is to act as a transcriptional co-activator, since the 
N-terminal region ofPygopus fused to a dominant negative form ofTCF can restore Wg 
signaling in Drosophila (Thompson, 2004). Further analysis of this domain including the 
proteins that bind to it, may reveal its exact function. The intervening regions of amino 
acids are rich in proline and glycine residues and show little sequence similarity between 
Pygo family members. At the C-terminus, Pygopus contains a highly conserved C4-H-C3 
zinc-binding domain. This domain is known as the Plant Homeodomain (PHD) (Aasland 
eta/., 1995), and it is thought to be involved in protein-protein interactions. The PHD 
domain has been implicated in the remodelling of chromatin, since it has been 
found in proteins that have known chromatin remodelling activity, including CBP 
(Bordoli eta/., 2001; Kalkhoven eta/., 2002). The only known function of the PHD 
domain in Pygopus is to mediate protein-protein interaction with Legless/Bcl-9, forming 
a bridge to the 13-catenin!fCF complex (Kramps eta/., 2002). Specific residues of the 
PHD domain ofPygo have been shown to be required for its binding to Bcl-9 and to relay 
the Wnt signal in normal development (Lin eta/., 2000; Townsley eta/., 2004). Given 
the fact that PHD domains are usually in proteins that have chromatin remodelling 
activity, Pygopus has been proposed to mediate the remodelling of chromatin to allow the 
TCF/f3.,;atenin complex to gain access to, and activate Wnt responsive promoters 
12 
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(Thompson eta/. , 2002; Kramps eta/., 2002), although there is no direct evidence to 
support this role. 
Limited studies to date outline the role ofPygopus proteins in Wnt signaling and 
normal development (Thompson eta/., 2002; Kramps eta/., 2002; Belenkaya eta/., 
2002; Parker eta/., 2002; Lake and Kao, 2003; Townsley eta/., 2004), but the exact roles 
of Pygopus proteins are still unknown. As well, the role of Pygopus in human cancer has 
not been directly addressed. While Pygo plays a role in Wnt signaling, aberrant Wnt 
signaling can contribute to formation of many types of tumours, as I will discuss in 
Section 1.2.4. 
1.2.3 Non-canonical Wnt Signaling 
As I have discussed in section I .2.1, the function of classical canonical Wnt 
signaling is to activate the key signaling intermediate, 13--catenin, and downstream 
TCFILEF responsive target genes. Non-canonical Wnt signaling (Figure 1.4), on the 
other hand, refers to other Wnt signaling pathways that have been identified after the 
initial discovery of the classical Wnt/~-catenin pathway. Non-canonical Wnt signaling 
can be divided into at least two distinct signaling pathways, the Wnt/Jun-N-terminal 
Kinase (JNK) and the Wnt/Ca2• pathways, both of which are mediated by a Wnt ligand 
binding to its frizzled receptor. 
The Wnt/JNK pathway, also known as the planar cell polarity pathway in 
Drosophila, involves the arrangement of cuticular cells that are lined up or polarized with 
respect to the body axis. It has been shown that the Frizzled receptor is required for this 
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Figure 1.4 Non-canonical Wnt signaling pathways. The binding ofWnt ligands to 
Frizzled receptors can also activate non-canonical Wnt signaling pathways responsible 
for planar cell polarity and convergent extension movements. The binding ofWnt to 
Frizzled can result in the intracellular increase in Ca2+ concentration, leading to the 
activation ofPKC, CamKII as well as a number of other proteins. The binding of Wnt to 
Frizzled can also result in the activation of the small GTPase, RhoA. Activation ofRhoA 
results in the activation ofthe c-Jun N-Terminal Kinase (JNK) pathway. 
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pathway, but the Wnt ligand that mediates this signal is currently unknown. The Frizzled 
receptor was found to be required for the polarity of wing hairs, or trichomes, in 
Drosophila (Vinson and Adler, 1987) and for the polarity of photoreceptor clusters, or 
ommatidia, in the Drosophila compound eye (Zheng eta/., 1995). This same pathway 
exists in the vertebrate Xenopus and was shown to regulate morphogenetic or convergent 
extension movements during gastrulation (Heisenberg eta/., 2000; Yamanaka eta/., 
2002). Non-canonical activation of Frizzled proteins can in tum, activate small GTPases, 
such as RhoA, which is a potent activator of the JNK pathway (Shulman eta/., 1998). 
Therefore, the activation of this non-canonical Wnt pathway appears to be very important 
for cell morphology, movements and adhesion during normal development. 
Activation of the non-canonical Wnt/Ca2+ signaling pathway ultimately results in 
an increase of intracellular Ca2+ ions, which can mediate a number of cellular responses. 
Frizzled protein receptors have a very similar structure to G-protein coupled receptors 
and it has been shown that activated Frizzled receptors can activate G-proteins resulting 
in the stimulation of phosphatidylinositol signaling and the subsequent intracellular 
release ofCa2+ ions (Slusarski eta/., 1997). Further study of Frizzled proteins and G-
protein signaling revealed that Frizzled receptors closely resemble G-protein coupled 
receptors (Barnes et a/., 1998). The increase in cytoplasmic Ca2+ concentration results in 
the activation of Protein Kinase C (PKC) and Calmodulin Kinase II (CarnKII) (Malbon et 
a/. , 2001; Malbon, 2004). It appears that the most important role ofCa2+ signaling in 
Xenopus embryonic development, for example, is in the formation of ventral structures 
and in its inhibitory effect on convergent extension movements mediated by canonical 
Wnt signaling, which is required for the development of dorsal structures (Kuhl, 2002). 
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1.2.4 Wnt Signaling and Cancer 
It is clear that Wnt signaling is important for the normal growth and development 
of an organism. Misexpression of Wnt signaling components in the early stages of normal 
development results in the formation of developmental defects, and in later stages of the 
growing adult, Wnt signaling is important for the normal growth and proliferation of cells 
and is therefore strictly regulated (Giles et a/., 2003 ). If this pathway becomes aberrantly 
deregulated in adult tissues, it may contribute to the uncontrolled growth and 
proliferation of cells, a primary characteristic of cancer. The normal function of Wnt 
signaling is to stabilize the key Wnt transducer, f3-catenin. Therefore, nearly all cancers 
that have identified mutations in Wnt signaling display an active nuclear form of 
f3-catenin, whose role is to promote the transcription of Wnt target genes. 
Overexpression ofWnt target genes, especially those involved in promoting cell cycle 
progression such as Cyclin D1 and c-myc (He et al., 1998; Tetsu and McCormick, 1999), 
can indeed contribute to the uncontrolled proliferation of cells. As well, there are many 
other documented Wnt target genes involved in cell movements and migration, such as 
several Matrix Metalloproteinases (MMP), such as MMP-7 (Brabletz eta/., 1999; 
Crawford eta/., 1999), and MMP-26 (Marchenko eta/., 2002). Overexpression of these 
genes may result in the ability of a cell to modiJY its extracellular environment and 
downregnlate cell-to-cell adhesion, characteristic of the malignant phenotype. 
Mutations in the Wnt signaling pathway have been identified and are thought to 
contribute to the malignancy of many tissue types. For example, Wnt mutations are most 
commonly identified in colorectal tissue. Loss-of-function mutations identified in APC 
are thought to be one of the main causes of a condition known as Familial Adenomatous 
16 
Chapter 1: Introduction 
Polyposis (FAP). FAP is a cancer characterized by the fonnation of hundreds to 
thousands of colorectal polyps which are caused by the inactivation of the tumour 
suppressor APC (Groden eta/., 1991; Nishisho eta/., 1991), which then results in the 
accumulation of~tenin and overexpression ofWnt target genes. Gain-of-function 
mutations have been identified in (}-catenin in colorectal cancer cell lines (Morin eta/., 
1997), and it has been hypothesized to be mutated in approximately I 0% of all colon 
cancers. On the other hand, the frequency of Wnt mutation in other cancers is relatively 
low. For example, mutations in Wnt pathway components are extremely rare in breast 
tumours. Yet surprisingly, some breast tumours display nuclear (3-catenin and Wnt target 
gene expression. 
1.2.5 Wot Signaling and Breast Cancer 
Earlier work implicated a role for the oncogene Inti (renamed to Wnt-1 after the 
discovery of Wg in Drosophila) in promoting mammary tumours. Retroviral infection of 
mice with the mouse mammary tumour virus results in its integration into the Inti locus 
of the host genome, resulting in the overexpression of the Inti gene. This induced 
overexpression of Inti was hypothesized to contribute to the fonnation of mammary 
tumours (Nusse and Varmus, 1982). These initial studies drew much attention to the role 
ofWnt/(3-catenin signaling in breast cancer, and despite all of the subsequent studies, 
there is still little known about the causes of the deregulation of ~lenin in breast 
cancer (Howe and Brown, 2004). Therefore, there is a need to identil)' the molecular 
causes of aberrant (3-catenin expression and nuclear localization in breast cancer. 
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Presently, there is strong evidence implicating a role for Wnt signaling in breast 
cancer due to the expression of nuclear localized 13--{;atenin. Significantly, it has been 
shown that the overexpression of a constitutively active form of (3-catenin in transgenic 
mice results in the formation of mammary tumours (Michaelson and Leder, 2001 ). In 
humans, cytoplasmic and nuclear overexpression of 13--{;atenin staining was observed in 
approximately 60% of breast tumours and also correlated with poor patient prognosis 
(Lin et a/., 2000; R yo et a/., 200 I). But studies demonstrating the frequency of genetic 
~lenin mutation in breast cancer was very low (van De eta/., 2001), therefore the 
nuclear localization of ~tenin observed in breast tumours is unlikely due to a direct 
mutation of the ~atenin gene. Therefore, proteins that directly interact with and 
regulate 13--{;atenin are likely involved in its aberrant expression and nuclear localization. 
I will classify these proteins into two groups for further discussion. The frrst group are 
proteins that are known to be directly associated with the Wnt signaling pathway, and the 
second group are proteins which are indirectly involved in the Wnt signaling pathway. 
There are many examples of Wnt signaling components whose aberrant 
expression may be correlated with the overexpression and nuclear localization of 
~tenin. Wnt ligands have been found to be overexpressed in breast cancers. For 
example, Wntl overexpression in transgenic mice results in the overexpression of target 
genes and the formation of mammary tumours (Li eta/., 2003) and Wnt5a expression is 
upregulated in primary breast cancers (Lejeune eta/., 1995). The upstream 
13--{;atenin regulator, Dsh was also shown to be overexpressed in primary breast tumours 
(Nagahata eta/., 2003), but it has not been correlated with the expression and localization 
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of [3-catenin. The overexpression of CK2 resulting in the phosphorylation and increased 
stability of [3-catenin, is suspected of contributing to aberrant Wnt signaling in breast 
cancer(Landesman-Bollag eta/., 2001). Uncommonly, there have been few studies in 
breast cancer that have identified genetic mutations in Wnt signaling intennediates 
resulting in pathway activation. For example, the key [3-catenin regulators, Axin 
(Webster eta/., 2000) and APC (Furuuchi eta/., 2000) have been shown to be mutated in 
a low percent of breast cancers. Therefore, there are many examples of how the 
overexpression or activation ofWnt pathway components may contribute to the 
stabilization and nuclear localization of J}-catenin and furthennore, the development of 
breast cancer. 
On the other hand, it is possible that [3-catenin nuclear localization may be due to 
misexpression of J}-catenin regulators indirectly involved in Wnt signaling. For example, 
it has been shown that [3-catenin expression and activity is downregulated by p53 (Sadot 
eta/. , 2001). This finding may help to explain the presence of nuclear f3-catenin in breast 
cancers that harbour p53 mutations. Also, hypennethylation of the APC promoter has 
been described in a significant number of breast cancers (Jin eta/., 2001 ). Promoter 
hypennethylation due to aberrant regulation of DNA methyl-transferases, may possibly 
result in decreased APC expression. This evidence therefore implies that the 
misexpression of proteins indirectly involved in Wnt signaling may result in the increased 
stability or activation of p~atenin in breast cancer. 
Nuclear f3-catenin participates in the expression of Wnt target genes by the 
fonnation of transcriptionally active complexes at WntlfCF consensus sites and there are 
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several studies of Wnt target gene expression in breast cancer. For example, the 
expression ofWnt target gene Cyclin D1 has been shown to be upregulated by 
approximately 50% in breast tumours, both at the messenger Ribonucleic acid {mRNA) 
level (Buckley eta/., 1993) and also at the protein level (Bartkova eta/., 1994). 
Overexpression ofCyclin Dl in the mammary gland of transgenic mice results in 
abnormal cell proliferation and the formation of mammary adenocarcinomas (Wang et 
a/., 1994). It has also been shown that a number of breast cancer cell lines exhibited high 
levels ofWnt dependent transcription correlating with the overexpression of the target 
gene Cyclin Dl (Lin eta/., 2000). It appears that not only Cyclin Dl is reqnired for 
tumourigenesis mediated by aberrant Wnt signaling, since Cyclin Dl knockout mice are 
susceptible to the formation of tumours mediated by the overexpression ofWntl (Yu et 
a/., 2001). Together, these results suggest that the activation ofWnt target genes may be 
necessary for the formation of mammary tumours. Further studies will be needed to 
demonstrate what other downstream Wnt targets alone or in combination, are necessary 
for mammary tumourigenesis. 
1.3 Expressional Knockdown Strategies using an Antisense Approach 
As I have discussed in section 1. I, cancers can arise from single cells that lose their 
ability to properly regulate cell growth and proliferation. This may result from genetic 
mutations in a cell either causing the underexpression of genes which are normally 
expressed at high levels, or from the overexpression of genes which are not normally 
expressed at high levels. A relatively new and important therapeutic approach to 
specifically target genes that are overexpressed in a disease state is to reduce or block 
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their expression. Many cancer cells and twnours have been shown to overexpress genes 
that lead to uncontrolled growth and proliferation, so reduction in their activities may be 
an important molecular therapeutic approach. 
Single genes and the information that they carry are stored in the form of DNA. In 
the living cell, the flow of genetic information from DNA to messenger ribonucleic acid 
(mRNA) and then to protein has been coined as the "central dogma" of molecular 
biology. The "knocking" down or reduction of the expression of a particular gene using 
an antisense approach usually involves targeting its mRNA and therefore inhibiting 
protein production. Antisense molecules specifically bind to the message or mRNA of a 
particular gene resulting in its degradation or the blocking of translation of that mRNA. 
There are a number of different ways to reduce the expression of a gene. In this thesis, I 
concentrated on the use of antisense oligonucleotides and short interfering RNA (siRNA) 
as tools for reducing the expression of a protein. 
Antisense oligodeoxynucleotides (ON) are usually short (15-25 bases), single 
stranded DNA molecules that are complementary to a given mRNA sequence. ON bind 
in a sequence specific manner by Watson and Crick base pairing to the complementary 
mRNA, resulting in the formation of an RNA-DNA duplex. There are several well 
known processes by which antisense ON can interfere with the production of protein 
from an mRNA (Figure 1.5). The binding of an antisense ON to its target mRNA 
sequence can result in ribosomal stalling during translation of mRNA into protein. 
Another well known mechanism by which the antisense ON can interfere with protein 
production is mediated by the nuclease, RNase H (Green eta/., 2000; Baker eta/., 2001; 
Crooke, 2004). RNase His a ubiquitously expressed enzyme in prokaryotic and 
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Figure 1.5 Knockdown of gene expression by antisense oligonucleotides. When 
introduced into tbe cell, antisense oligonucleotides base pair to the complementary 
sequence of a target mRNA, resulting in a decrease in protein production. The formation 
of a DNA/RNA complex is recognized and degraded by the intracellular nuclease, 
RNaseH. Inhibition of translation can also occur due to ribosomal stalling at the site of 
the DNA/RNA complex. 
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eukaryotic cells. In humans, RNase HI recognizes and cleaves the RNA strand of an 
RNA-DNA duplex, resulting in degradation of the mRNA species (Wu et al., 1999). 
Therefore, the use of antisense ON can exploit known mechanisms of RNA regulation to 
experimentally manipulate the down regulation-of gene expression. 
The discovery that double stranded RNAs have inhibitory effects on gene 
expression, or RNA interference (RNAi), was first demonstrated in Caenorhabditis 
elegans (Fire et al., 1998). In fact, RNAi has been found to be a useful tool and 
mechanism in mammalian cells to knock down gene expression. In the cell, double 
stranded RNA (dsRNA), that either occurs naturally or is introduced, is specifically 
recognized by an RNase III ribonuclease, known as Dicer (Bernstein et al., 2001) (Figure 
1.6). This enzyme is responsible for the Adenosine Triphosphate (A TP)-dependent 
cleavage or processing of dsRNA into siRNAs, which are 21-23 nucleotide duplexes of 
dsRNA. siRNAs are then incorporated into an RNA induced silencing complex (RISC), 
where they are unwound in an ATP--dependent manner. Target mRNAs are then recruited 
to the antisense siRNA and are cleaved by the RISC, which initiates the degradation of 
the RNA (Denli and Harmon, 2003; Dykxhoom eta/. , 2003; Shi, 2003). 
The use ofRNAi has evolved as a useful method to knock down gene expression 
in manunalian cells. For example, it has been shown that this may be particularly useful 
for the study of overexpressed genes. siRNAs directed against J3-catenin are effective at 
inhibiting the growth of human colon cancer cells which display activating mutations in 
Wnt signaling and overexpression ofj3-catenin (Verma eta/. , 2003). Therefore, the use 
of siRNA to reduce gene expression in humans likely represents a new therapy based 
future treatment of disease. 
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Figure 1.6 Mechanism of RNA degradation by RNA interference. The generation of 
siRNA can result in the degradation of a target mRNA. Double stranded RNA ( dsRNA) 
molecules are cleaved into short interfering RNA (siRNA) by the RNaseiii enzyme 
known as Dicer, in an A TP dependent manner. A TP is also necessary for the unwinding 
of the siRNA by the RNA induced silencing complex (RISC). The antisense strand of the 
siRNA is displayed by the RISC, binds to the target mRNA and is cleaved by the RISC. 
This process results in the degradation of mRNA and the inhibition of protein production. 
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1.4 Thesis Rationale 
Misexpression of Wnt signaling has been implicated in the progression of human 
cancer. Misexpression or mutations in Wnt signaling components results in the activation 
and nuclear localization of the key signaling intermediate, 13-catenin. Nuclear 
p-catenin then interacts with a multi protein complex to activate the expression of Wnt 
target genes. Indeed, the overexpression of Wnt target genes is associated with the 
malignant phenotype as was discussed in Sections 1.2.4 and 1.2.5. Many cancers display 
the active nuclear localized form of !3-catenin, as well as Wnt target gene overexpression. 
This has been most commonly identified in colorectal cancers that frequently harbour 
activating mutations in Wnt signaling intermediates, although a significant number of 
breast cancers also exhibit Wnt signaling activation by nuclear f3-catenin expression (Lin 
eta/. , 2000; Ryo eta/., 2001) by an unknown molecular mechanism. 
Pygopus, a novel component ofWnt signaling, has been shown to be a 
downstream mediator ofWnt signaling (Thompson eta/. , 2002; Kramps eta/. , 2002). To 
date, a limited number of studies have outlined the role ofPygopus proteins in Wnt 
signaling and normal development (Thompson eta/., 2002; Kramps eta/., 2002; 
Belenkaya eta/., 2002; Parker eta/., 2002; Lake and Kao, 2003; Townsley eta/., 2004), 
but there have been no studies that directly implicate a role for Pygopus in human cancer. 
It has been previously shown that knockdown ofPygopus in colorectal carcinoma cells 
by RNAi resulted in a decrease ofTCF/13-catenin driven transcription (Thompson eta/., 
2002), therefore confirming its role in Wnt signaling. Other than this requirement, it is 
not clear whether or not the cells required Pygo for their growth or survival. 
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It has been hypothesized that aberrant Wnt signaling contributes to the malignancy 
of breast cancer and that nuclear ~tenin has been observed in a large number of breast 
cancers. The purpose of this thesis was to determine the expression and requirement of 
Pygopus in breast cancer, given the central role of the canonical Wnt signaling pathway 
in this malignancy. My hypothesis is that the overexpression ofPygopus may contribute 
to the growth of breast cancer cells. Therefore, the objectives of my study were: 
I. To design a protein antigen against the non-conserved regions of the human 
Pygopus2 (hPygo2) protein and use it to immunize rabbits. The resulting antiserum will 
then be collected and characterized. 
2. To examine the expression of human Pygopus family members as well as the 
expression of other downstream Wnt components which have been shown to interact with 
Pygopus in a variety of normal and cancer cells, including breast cell lines and tumours 
3. To address the requirement ofhPygo2 in the growth of human cancer cells 
including breast cancer cells by designing antisense ONs to specifically target hPygo2, 
but not the closely related family member, human Pygopus 1 (hPygo 1 ). 
4. To address the role ofhPygo2 in the regulation ofWnt dependent transcription 
in breast cancer cells. 
My results are the first to demonstrate the expression ofPygopus in breast cancer. 
I have found that hPygo2 mRNA and protein are expressed at high levels in the nuclei of 
malignant breast cancer cells and at low levels in normal breast cells and tissue. Tbis 
expression of hPygo2 was strongly correlated with the expression of the key Wnt 
signaling mediator ~tenin, but not with other newly discovered components of the 
pathway, including hPygo1 and Bcl-9. I have also demonstrated that hPygo2 but not 
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j3-{:atenin was required for the growth of human cancer cells, including the two breast 
cancer cell lines MCF-7 and MDA-MB-468. Furthermore, the reduction of cell growth 
due to hPygo2 knockdown was accompanied by a reduction in the cell cycle regulatory 
protein and Wnt target gene, Cyclin 01. Finally, I have demonstrated that hPygol but not 
hPygo2 functions as an activator of the Wnt signaling, indicating an alternative role of 
hPygo2 outside of the canonical Wnt signaling pathway in the mediation of breast cancer 
cell growth. 
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CHAPTER2 
MATERIALS AND METHODS 
2.1 Production of hPygo2 Antiserum 
2.1.1 Production of Purified GST fusion hPygo2 Proteins 
Regions encoding amino acids 1-45 and 74-312 ofhPygo2 (accession number 
NM _138300) that were selected for antibody production lacked the conserved NHD and 
PHD regions, therefore reducing the potential for cross reactivity with other proteins that 
contain these protein domains. The regions were also tested for antigenic sites using the 
online program "Antigenic" (http://bioweb.oasteur.fr/seganaVinterfaces/antigenic.html), 
which can be used to predict antigenic sites within a protein, based on the hypothesis that 
regions of hydrophobic residues that are located on the surface of a protein are more 
likely to be antigenic (Kolaskar and Tongaonkar, 1990). hPygo2 inserts were PCR 
amplified with the following primers: hPygo2 (1-45) (F: 5'-
GTCCCCCACTCCATGGCCGCCTCG; R: 5' -TCATCGCTTCTTTTCTGGACTCTTC) 
hPygo2 (74-312) (F: 5' -GCATCCAACCCTTTTGAAGATGAC; R: 5'-
TCAGCCAGGGGGTGCCAAGCTGTTG) from l.MA.G.E. Consortium {l.LNL) 
hPygo2 complementary DNA (eDNA) clones (CioneiDs: 41570072 and 3627860) 
obtained from Incyte Genomics Inc. PCR products were ligated in frame with the 
Glutathione S Transferase (GST) tag in the EcoRJ andXhol restriction sites ofpGEX-
4Tl {Amersham) using T4 DNA Ligase (Invitrogen). The resulting plasmids were then 
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midi-prepped (grown in 150 ml Luria-Bertani media containing 50 Jl!Yml ampicillin at 
31'C overnight, and harvested by the alkali-lysis method (Birnboim, 1983)) using the 
Qiagen Hi Speed Plasmid Midi Kit. DNA sequencing was performed by the 
dideoxynucleotide chain termination method (Sanger eta/., 1977), using the USB 
Sequenase Version 2.0 kit (Amersham) to confirm specificity. The resulting purified 
GST fusion proteins were synthesized and isolated from BL-21 Codon Plus RP, 
competent E. coli cells (Stratagene) (a gift from Dr. G. Paterno) and purified over 
Glutathione Sepharose 4B beads (Amersham) as per the GST Gene Fusion System 
(Amersham) protocol. Proteins were then concentrated using Centricon-10 protein 
concentrators (Amicon), resuspended in Phosphate buffered saline (PBS) and stored at-
70"C. Purified proteins were analyzed by 10% sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) then staining gels with Coomassie blue (Sigma) or by 
western blotting with an anti-GST antibody (Santa Cruz). Approximate protein 
concentration was determined using the BioRad reagent as per the manufacturers' 
instructions. 
2.1.2 Production ofhPygo2 Antiserum 
Preimmune serum was collected prior to immunization of New Zealand White 
rabbits (Charles River Laboratories). The purified GST-hPygo2 fusion proteins were 
reconstituted using the Ribi Adjuvant System (Corixa), as per manufacturer's protocol. 
Two rabbits per protein construct were injected with approximately 40Q )lg of the 
appropriate GST fusion protein. Injections were performed in three week intervals, the 
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first two injections were intramuscular and subsequent injections were subcutaneous. 
After the third boost, serum was collected as described (Ryan and Gillespie, 1994). 
Briefly, approximately 20-30 ml of blood was collected into a 50ml sterile Falcon Tube 
by ear artery catheterization. Sodium azide was added to a final concentration ofO.Ol% 
to prevent microbial growth and the blood was incubated at room temperature for 6-8 
hours to allow a clot to form. The resulting serum was isolated by centrifugation on a 
clinical centrifuge and stored at -20°C. 
2.1.3 lmmunoprecipitation of in vitro Translated hPygo2 Protein 
35S labeled hPygo2 protein was prepared using the coupled transcription-
translation cell free system (Promega), as per manufacturer's instructions, using 
pCS2+/hPygo2 (see plasmids section 2.4.1) as a template. For immunoprecipitation (IP), 
in vitro translated hPygo2 protein was combined with 10-20 J!( of preimmune or immune 
serum in IX Triton IP buffer (10 mM Tris pH 7.5, 1% Triton-X-100, lOmM EDT A, 
0.002% sodium-azide, 20mM Methionine, lmM phenylmethylsulfonyl fluoride, 10 
J!g/ml aprotinin, 10 J!g/mlleupeptin and 50 J!g/ml Nor-P-tosyi-L-Iysine chloromethyl 
ketone) and rotated overnight at 4°C. After overnight incubation, 50 J!l of a 50% slurry of 
Protein A Sepharose (Amersham), prepared as per manufacturer's protocol, was added 
and furtber incubated for lhr at 4°C. Finally, beads were washed three times with ice cold 
IX Triton IP buffer and three times with an ice cold !50 mM solution ofNaCI. Proteins 
were eluted in protein sample buffer and analyzed by SDS-PAGE. Exactly one balf of in 
vitro translated hPygo2 protein was used as a positive control. 
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2.2 Cell Culture 
All cell lines, except normal endocervical (HEN) and normal ectocervical (HEC) 
cell lines (Tsutsumi eta/., 1992), were purchased from the American Type Culture 
Collection. T98G and Sk-N-Sh cells were maintained in Minimal Essential Media (Gibco) 
supplemented with 10% fetal bovine serum (FBS) (Gibco). MDA-MB-231 cells were 
maintained in Leibovitz's L-15 Medium (Gibco) supplemented with 10% FBS. HEN and 
HEC cells were maintained in Keratinocyte Serum Free Media (Gibco ). Sk-Ov-3, Es-2, 
HeLa, Caski, Hs-574, BT-20, Bt-474, MCF-7, MDA-MB-157 and MDA-MB-468 cells 
were all maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco) 
supplemented with I 0% FBS. Hs-578Bst and Hs-578T were both maintained in DMEM 
supplemented with 10% FBS with IOJ-lg/ml insulin_ Hs-578Bst cells were further 
supplemented with 30ng/ml Epidermal Growth Factor. All cells were maintained in a 
humidified atmosphere with 5% C02 at a temperature of37"C, except MDA-MB-231, 
which were maintained in a humidified atmosphere with 0% CO, at a temperature of 
37"C. 
2.3 Expression Analysis 
2.3.1 Northern Analysis 
Total RNA was extracted from cell lines using the Nucleospin RNA II Kit 
(Clontech Laboratories Inc.). Approximately 5J-1g of total cellular RNA from all cell lines 
was run on a formaldehyde gel and transferred to Gene Screen TM hybridization 
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membranes (Dupont). RNA was then UV crosslinked to the membranes and dried. A 
PCR product ofhPygo2 was generated with hpygo2 (74-312) primers described in 
section 2.1.1, and was purified with a DNA gel extraction kit (Millipore). The purified 
PCR template was then radioactively labeled with a32P~ TP by random priming 
(Prime-a-Gene; Promega), according to the manufacturers protocol. Blots were 
hybridized at 60" C using ExpressHyb (Clontech Laboratories Inc.), washed at high 
stringency (60°C in 0.1%SDS and O.IXSSC) and reprobed with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (pTRI-GAPDH; Arnbion) under the same 
hybridization conditions to ensure equal loading and transfer of RNA 
2-3.2 RT-PCR Analysis 
Cells in culture were harvested by trypsinization and briefly washed with ice cold 
lXPBS. Total RNA was extracted from cell lines using the Nucleospin RNA II Kit 
(Clontech Laboratories Inc.). Reverse Transcription-PeR (RT-PCR) was performed 
essentially as described (Lake and Kao, 2003). Briefly, RNA was reverse transcribed 
using MML V reverse transcriptase (Invitrogen). PCR cycling parameters included: 
denaturation at 94 "C for 4 minutes, hybridization of primers to target sequences for 4 5-60 
seconds, at temperatures specified in Table 2.1, and elongation at 72"C for 45-60 seconds. 
During the last cycle instead of 45-60 seconds, elongation occurred for 7-10 minutes. 
PCR products were electrophoresed on 1-1.5% agarose gels and photographed under UV 
light. Equal levels of eDNA used in the PCR reactions were achieved by normalization to 
GAPDH levels. Primers used in the analysis included those complementary to hpygo2 
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(74-312), hPygo1 (accession numberNM_015617) F: 5'-
GCCACGACAACCAAGAGGTG; R: 5'-CCAGTACAGATCCGATGAAACC, Bcl-9 
(accession numberNM_ 182557) F: 5'-GATGTTGTCCTGGTGTCTTG; R: 5'-
GGTCACGACACTGCAGTGCTC and GAPDH (Ju eta/., 1995) All primers for RT-
PCR were synthesized by Invitrogen. 
Table 2.1 Primer Hybridization Conditions 
Primer TA*("C) N** Reference 
hPygo2 60 30 
hPygol 60 30 
Bcl-9 55 30 
GAPDH 55 23 Ju et al., 1995 
• Annealing temperature 
••Number of annealing/elongation cycles 
2.3.3 Immunoblot Analysis 
Total protein from tissue culture cells was extracted in protein sample buffer. 
Approximate concentration of protein was determined using the Biorad assay reagent. 
Approximately 50 J!g of total cell lysate was separated by SDS-PAGE and transferred to 
nitrocellulose membranes (Hybond-ECL "'; Amernham). Blots were probed with the 
following antibodies: monoclonal GST (Santa Cruz), monoclonal and polyclonal 
j3--<:atenin (Santa Cruz), monoclonalj3-Actin (Sigma), monoclonal Cyclin OJ (BD 
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Biosciences), and polyclonal hPygo2. As a positive control for hPygo2, in vitro translated 
hPygo2 protein was prepared using the coupled transcription-translation cell-free system 
(Promega). Blots were then visualized by enhanced chemiluminescence (Amersham). To 
confimt equal loading of protein, blots were reprobed with f3-Actin. 
2.3.4 Immunocytochemistry 
For immunofluorescent analysis Hs-574-mg, Bt-474 and MCF-7 cells were fixed 
in 4% paraformaldehyde (30 minutes) rinsed in PBS twice and 0.2% triton-X 100/PBS 
(!PBS) for I 0 minutes. Cells were blocked in I 0% normal donkey/goat serum prior to an 
overnight incubation with primary antibodies in 1.5% normal sera/PBS. After a 30 to 
40 minute wash in 0.2% lPBS, cells were incubated 30 minutes with secondary 
antibodies in 1.5% normal sera. For hPygo-2, biotinylated donkey anti-rabbit (Amersham) 
and for 13-Catenin, Cy3 donkey anti-mouse (Jackson ImmunoResearch Laboratories, Inc.) 
was used. After a 30 to 40 minute wash in 0.1 - 0.2% lPBS, cells were incubated in 
streptavidin fluorescein (Amersham) in 1.5% normal sera/PBS for 30 minutes. Cells were 
washed in 0.1-0.2% lPBS 30 to 40 minutes before mounting in I 0% glycerol/PBS or 
Vectashield (Vector Laboratories, Inc.). Images were collected using confocal 
microscopy (Olympus). 
2.3.5 Immunobilltocbemilltry 
Breast tumour sections were obtained from the Memorial University Division of 
Laboratory Medicine. Immunohistochemistry was carried out as previously described 
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(Rorke et a/., 2001). Briefly, tumour sections were deparaffinized in Xylene and then 
rehydrated in a graded ethanol series to distilled water. Endogenous peroxidase activity 
was blocked in a 3% solution of H20 2 and then washed briefly in distilled water. To 
retrieve/unmask the antigen, sections were incubated in a boiling solution of 10 mM 
Citrate buffer, pH 6.0 and then cooled and washed with a running tap water bath. Slides 
were then washed with PBS and placed in a humid chamber. Slides were blocked in a 
10% normal goat serum/PBS. All antibody dilutions were made up in a solution of 1% 
bovine serum albumin in PBS. Pre-immune and hPygo2 primary antibodies were added 
at a predetermined dilution and incubated overnight at 4°C. Slides were then rinsed with 
PBS and incubated with a biotinylated goat anti-rabbit IgG (Zymed) secondary antibody, 
rinsed again with PBS and incubated with an HRP-streptavidin antibody (Zymed). Slides 
were rinsed in PBS and incubated with a solution of DAB (Sigma) and H20,, until a 
brown colour developed. Slides were again, rinsed with PBS and counterstained with 
Ehrlich's hematoxylin (Sigma) and destained in water, acid alcohol (70% ethanol, 1% 
concentrated HCI), tap water, and Scott's Tap Water Substitute (2-3.5g/L Sodium 
bicarbonate, 20 giL Magnesuim sulfate). Slides were then dehydrated in a graded ethanol 
series to Xylene, then mounted with Permount (Sigma) and allowed to dry overnight. 
2.4 Functional Analyses 
2.4.1 Plasmids 
Mammalian hPygo2 expression constructs were produced by subcloning hPygo2 
from pOTB7/hPygo2 (engineered by Dr. B. Lake) and insertion into pCS2+ (a gift from 
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Dave Turner). The full length hPygo2 construct (pCS2+/hPygo2) was prepared by 
releasing the hPygo2 insert from pOTB7/hPygo2 and ligating it into the EcoRI and Xhol 
restriction sites of pCS2+. pCS2+/hPygo2 was sequenced with the USB Sequencing Kit 
(Amersham) to confirm specificity. 
Gal-4-hPygo2 fusion proteins were constructed by PCR amplification of different 
regions of hPygo2 (primers given in Table 2.2) followed by the insertion into the EcoRI 
and Xho/ restriction sites of pCMV-Tag2b (Stratagene ). hPygo2 inserts were then 
subcloned from pCMV-Tag2b into the EcoRI and Hindlll restriction sites of pMG4 to 
make N-terminal Gal-4-hPygo2 fusion proteins. All plasmids were sequenced with the 
USB Sequencing Kit (Amersham) to confirm correct insert sequences. hPygol and Bcl-9 
expression constructs were prepared by PCR amplification from a human mammary 
carcinoma eDNA (Clontech). hPygol was then ligated into the BamHI and EcoRI 
restriction sites of pCMV-Tag2b and Bcl-9 was ligated into the Hindlll and Sal/ 
restriction sites ofpCMV-Tag2c. A full length expression construct of j}-catenin S37A 
was prepared by RT -PCR amplification of (3-catenin from the ovarian cancer cell line 
TOV-112D, which harbors a homozygous (3-catenin missense mutation resulting in an 
amino acid substitution of a Serine residue to an Alanine residue at amino acid position 
37 (Wu et a/. , 2001) and inserted into the BamHJ and Cia! restriction sites of pCS2+. 
Primers used included hPygol (accession numher NM_Ol5617) F: 5'-
GCCACGACAACCAAGAGGTG; R: 5' -CCAGTACAGATCCGATGAAACC, 
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Table 2.2 Primer Sequences and PCR Conditions for Gal-4-bPygo2 Constructs 
Construct Upstream primer (5'-3') Downstream primer (5'-3') TA* N** 
Gal-4- GTCCCCCACTCCAT- TCAGCCAGGGGGTG- 60 
bPygo2-1 GGCCGCCTCG CCAAGCTGTTG 
Gal-4- ATGGCTCCAAAGAAG- TCACCCATCGTTAGC- 60 
bPygo2-2 AAGCGTAAGGTACAG- AGCC 
CCTCCCCCAGGCTTGG 
Gal-4- ATGGCTCCAAAGAAGA- TCAGCCAGGGGGTG- 60 
hPygo2-3 AGCGTAAGGTAGCATCC- CCAAGCTGTTG 
AACCCTTTTGAAGATGAC 
Gal-4- GTCCCCCACTCCATG- CCAAGGAA TGGAGG- 65 
bPygo2-4 GCCGCCTCG GGCTGCAAC 
Gal-4- ATGAAGAGTCCAGAA- CCAAGGAATGGAGG- 65 
hPygo2-5 AAGAAGC GGCTGCAAC 
Gal-4- ATGAAGAGTCCAGAAA- TCACCCATCGTTAGC- 60 
hPygo2-6 AGAAGC AGCC 
• Primer annealing temperature 
**Number of annealing/elongation cycles 
Synthetic nuclear localization sequence is in bold 
Synthetic stop codon is underlined 
Bcl-9 (accession number NM _ 182557) F: 5' -GATGTTGTCCTGGTGTCTTG; R: 5 '-
GGTCACGACACTGCAGTGCTC and f3--eatenin (accession number NM_001904) F: 
5'-ATGGCTACTCAAGCTGATTTGATGG; R: 5'-
CCTAAAGGATGATTTACAGGTCAG. All plasmids were sequenced with tbe USB 
Sequencing Kit (Amersham) to confirm correct insert sequences. 
37 
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35 
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2.4.2 Transfection of Plasmid Constructs 
All transfections with plasmid constructs were performed with 
Lipofectamine/Pius (Invitrogen), as per manufacturer's protocol. Growth media was 
replaced every 24 hours. 
For western analysis of Gal-4-hPygo2 protein constructs, HeLa cells were seeded 
at a density of 7.5 x 104 cells/well in twelve well plates. 0.5 J.Lg of plasmid were 
transfected and total cell protein was extracted 48 hours after transfection. Approximately 
50 1-1g of the protein extracted was used for western analysis. 
2.4.3 Antisense Oligonucleotides and siRNA 
Antisense oligonucleotides (Table 2.3) (Invitrogen) against hPygo2 were designed 
to contain three phosphorothioate bonds at each terminus to enhance nuclease resistance. 
All oligonucleotides were designed avoiding Guanine quartets (GGGG) and repeated 
Cytosine Guanine (CG) sequences which may result in non-specific antisense effects 
(Green eta/., 2000; Baker et al., 2001). 
J3-catenin siRNA and non-specific control siRNA were purchased as a 
l3~tenin siRNA/siAB 1M Assay Kit (Upstate). 
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Table 2.3 Antisense Oligonucleotide Sequences and Binding Positions 
Oligonucleotide 
Non-specific 
Mismatch5 
Sequence (5'-3') 
T*T*T*GCGCCGTTTCTT*C*T*C 
G*!;;*C*TGAGCIAA TCATT*G*G*I 
Binds RNA 
(nt position on 
eDNA 
G*A*G*CTGCAGCAACCACA*A*A*G 55-74 
2 G*G* A *CCCGGGTT AGCGGCA *G*C*G 144-164 
3 C*C*A*CCTCCCTCCAGCTTG*T*C*C 198-219 
4 G*G*A*GGACTAAAGTTTT*G*A*C 687-705 
5 G*G*C*TGAGCAAA TCGTT*G*G*G 807-825 
6 G*A*A*AAGCAGTAGAAGCA*G*G*T 967-986 
7 C*T*C* ACGGA TGT AGAC* A *G* A 1340-1357 
8 C*C*T*CTGGCCAGAAAC*T*T*T 1817-1835 
9 C*T*C*TTCTACCTTTGAG*T* A *C 2434-2452 
10 C*A*C*TGTATCTTGAGC*T*G*G 2720-2737 
Mismatches are underlined 
* indicates a phosphorothioate bond 
2.4.4 Transfection of Oligonucleotides and siRNA 
All transfections with oligonucleotides and siRNA were performed with 
Oligofectamine (Invitrogen) as per the manufacturer's instructions, replacing the growth 
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media every 24 hours. For HeLa and MCF-7 cells, hPygo2 antisense/control 
oligonucleotides were transfected to a final concentration of250 nM and all siRNAs were 
transfected to a final concentration of tOOnM. For MDA-MB-468 cells, hPygo2 
antisense/control oligonucleotides were transfected to a final concentration of 67.5 nM 
and all siRNAs were transfected to a final concentration of 25oM. For RT-PCR analysis, 
HeLa cells were seeded at a density of 1.5 x to' cells/well in six-well plates and were 
harvested 24 hours after transfection for RNA extraction. For Western analysis, MCF-7 
and MDA-MB-468 cells were seeded at a density of to' cells/well in twelve-well plates. 
Protein was extracted at 48 and 72 hours respectively. HeLa cells were seeded at 7.5 x 
t04 cells/well in six-well plates, and were harvested 48 hours after transfection. Finally, 
for cell growth analysis cells were seeded in triplicate at a density of7.5 x t04 cells/well 
for MCF-7 and MDA-MB-468 cells and 5 x t04 cells/well for HeLa in twelve-well plates. 
Cells were counted 48 and 72 hours after transfection using trypan blue exclusion (Sigma) 
with a hemacytometer. 
2.4.5 Luciferase (TOPFLASB) Wnt Reporter Assay 
Approximately t8 hours prior to transfection, MCF-7 cells were seeded in 
triplicate at a density of 1.5 x to' cells per well in t2-well plates. Cells were transfected 
using the Lipofectamine Plus reagent (Invitrogen). 0.5 jlg of either pTOPFLASH-Luc, a 
positive control reporter plasmid containing TCF/LEF-1-binding sites, or with 
pFOPFLASH-Luc, a negative control plasmid having mutant binding sites, were 
transiently transfected along with molar equivalents of pCS2+ or pCS2+/ 
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!3-catenin S37A, in combination with pCMVTag2b, pCMVTag2blhPygol, 
pCMVTag2blhPygo2 or pCMVTag2clhBcl-9. 
Cells were harvested 48 hour.; after transfection by trypsinization, followed by 
two washes in IX PBS. Luciferase assays were performed on celllysates using a 
Monolight 2010 Luminometer (Analytical Luminescense Laboratory) with the Luciferase 
assay reagent (Prom ega), according to the manufacturers' instructions. Briefly, cell 
pellets were resuspended in 50-100111 of IX reporter lysis buffer, incubated on ice for 30 
minutes and then centrifuged at 16000 x g for 2 minutes at 4 •c. Soluble supernatant was 
collected and stored at -70°C until needed. I 0-20 !11 of cell lysate was then added to 
100 111 ofluciferase assay reagent and then luciferase activity was determined 
immediately. The values obtained in relative luciferase units (RLU), were normalized to 
the total amount of protein in the sample. Each experiment was performed in triplicate 
and was repeated three times. 
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Chapter 3: Results 
There are a limited nmnber of studies to date outlining the role ofhmnan Pygopus 
2 in hmnan cancer. Therefore, the main objectives of my experiments were to: (I) 
generate and characterize an antibody directed against hPygo2, (2) examine the 
expression ofhPygo2 and other Wnt signaling components in a nmnber of cancer cell 
lines and breast tumours, (3) address the requirement and functional role of hPygo2 in 
cancer cell growth, and finally to (4) address the role ofhPygo2 in the transcription of 
Wnt target genes. 
3.1 Production and characterization of hPygo2 antibodies 
For the production of an hPygo2 antibody, purified hPygo2 proteins were made 
which could be used as antigens to generate polyclonal antibodies when injected into 
rabbits. 
3.1.1 Production of purified GST-fusion hPygo2 proteins 
In order to purifY different antigenic regions ofhPygo2, GST -fusion proteins of 
hPygo2 were prepared. The GST epitope was then used to affinity purifY the resulting 
GST-hPygo2 fusion proteins. Following the purification and concentration steps, the 
GST -hPygo2 fusion proteins were then analyzed by SDS-PAGE (Figore 3.1 ). Purified 
GST migrated to its expected size of approximately 30 kDa. The GST-hPygo2 (1-45) 
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Figure 3.1 Production of purified GST-bPygo2 fusion proteins. The protein maps of 
the GST-hPygo2 fusion proteins, GST-hPygo2 (1-45) and GST-hPygo2 (74-312) are as 
indicated Purified proteins were separated by SDS-PAGE and stained with Coornassie 
blue. GST migrated to approximately 30 kDa and GST-hPygo2 (1-45) migrated to 37 
kDa. GST-hPygo2 (74-312), on the other hand migrated to 60 kDa, with protein 
degradation/truncation products migrating to approximately 32-37 kDa. Sizes of 
molecular weight markers are indicated. 
GST 
hPygo2 
1 406 
c1 =ccu ..... ~======~ .... .ol 
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fusion protein migrated as a single band to approximately 35 kDa. The full GST -hPygo2 
(74-312) fusion protein on the other hand, migrated to approximately 60 kDa, although 
protein degradation/truncation products were detected and were between 30-35 kDa in 
size. To confirm that all proteins that were produced were indeed GST-fusion proteins, 
western analysis was performed with an antibody against GST (Figure 3.2). All GST-
hPygo2 fusion proteins migrated to the same sizes as determined in Figure 3.1. This 
analysis also confirmed that the degradation/truncation products in the GST -hPygo2 (74-
312) lane were indeed GST fusion protein products and not due to contaminating 
bacterial proteins. The absence of other bands indicated that both GST -hPygo2 fusion 
proteins were indeed pure and therefore could then be used for injection into two rabbits. 
GST-hPygo2 (1-45) was used for injection into two rabbits (named: Puddin and Thumper) 
and GST -hPygo2 (74-312) was injected into two different rabbits (named: Hausenpfeffer 
and Smidgen). 
3.1.2 Characterization of hPygo2 antibodies 
3.1.2.1 Immunoprecipitation orin vitro transcribed/translated hPygo2 protein 
To test the ability of the hPygo2 antisera to bind to hPygo2 protein, 
immunoprecipitation was performed using in vitro transcribed/translated 35S-labeled 
hPygo2 protein. As can be seen, immune sera from all four rabbits was able to bind to 
and pull down approximately 50% oflabeled hPygo2 protein (IP: first bleed; Figure 3.3 
a). In contrast, pre-immune serum (IP: pre-immune) used at the same dilution as the 
44 
Chapter 3: Results 
45 
Figure 3.2 Western analysis ofGST-hPygo2 fusion proteins. Western analysis was 
performed on the purified GST-hPygo2 fusion proteins using an antibody that recognizes 
GST. All purified proteins migrated to their expected sizes. The degradation products of 
GST-hPygo2 (74-312) were also recognized by the anti-GST antibody, indicating that 
they contain GST and are likely degradation/truncation products of the GST-hPygo2 (74-
312) protein. Relative positions of molecular weight markers are indicated 
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Figure 3.3 Confirmation of the ability of the hPygo2 antiserum to bind to hPygo2 
protein. In vitro transcribed/translated hPygo2 was immunoprecipitated with the hPygo2 
antiserum collected. 50% of the labeled hPygo2 protein was loaded on the gel as a 
positive control. Rabbit serum used is as follows: 1 Puddin, 2 Thumper, 3 Hausenpfeffer, 
4 Smidgen (a) lmmunoprecipitation ofhPygo2 with first bleed immune serum. 
Preimmune serum was used as a negative control. (b) Immunoprecipitation using first 
and second bleed immune serum. 
a 
b 
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immune sera did not bind to the hPygo2 protein. These results indicate the immune sera 
contains antibodies that specifically interact with the labeled hPygo2 protein. 
I also compared the ability of first and second bleed hPygo2 antisera to bind to 
and immunoprecipitate hPygo2 protein (Figure 3.3 b). As can be seen, levels ofhPygo2 
protein irnmunoprecipitated by the Thumper, Hausenpfeffer and Smidgen antisera did not 
significantly change between the first and second bleed. Puddin antiserum, on the other 
hand, showed a significant increase in its ability to bind to the labeled hPygo2 protein. 
3.1.2.2 Western analysis of bPygo2 protein 
The hPygo2 antiserum was previously shown to bind to non-denatured hPygo2 
protein (Section 3.1.2.1). I next wanted to determine if the antiserum against hPygo2 was 
able to interact with denatured protein using western analysis to be used for future 
experiments. 
The hPygo2 antisera from all four rabbits were able to detect the denatured 50 
kDa in vitro transcribed/translated hPygo2 protein by western analysis (Figure 3.4 a). 
There was some non-specific banding that occurred at higher and lower molecular 
weights than hPygo2 in all of the immunoblots. The lower molecular weight banding in 
the blots probed with Hausenpfeffer and Smidgen antisera are likely truncations of the 
hPygo2 protein, as they were also present when the blots were exposed to reveal the 
relative position of35S-labeled hPygo2 protein (Figure 3.4 b). Hausenpfeffer antiserum 
gave the lowest amount of non-specific banding and was used for further experiments. 
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Figure 3.4 Test of immune serum for western analysis. In vitro transcribed/translated 
35S labeled hPygo2 protein was separated by SDS-PAGE and immunoblotted with 
immune serum that was collected from all four rabbits. (a) Western analysis of in vitro 
translated hPygo2 protein with Puddin, Thumper, Hausenpfeffer and Smidgen immune 
serum. All antibodies recognize a band that corresponds to hPygo2 at approximately 50 
kDa. (b) After the chemiluminescent signal had been reduced, the nitrocellulose 
membranes from (a) were dried and exposed to film to reveal the 35S labeled hPygo2 
protein hPygo2 appears as a band at approximately 50 kDa. The relative position ofthe 
49.5 kDa molecular weight marker is indicated. 
a 
49.5kDa.,... 
b 
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To confirm the ability of the Hausenpfeffer antiserum to detect different portions 
of the hPygo2 protein, HeLa cells were transiently transfected with different regions of 
the hPygo2 protein fused to Gal-4 (Figure 3.5 a). The transfected Gal-4-hPygo2 
constructs were detected in HeLa cell lysate by immunoblorting with the Hausenpfeffer 
antiserum, targeting the hPygo2 protein (Figure 3.5 b). The hPygo2 antibodies present in 
the Hausenpfeffer antiserum detected all Gal-4-hPygo2 tagged proteins, except for the 
transfected Gal-4 tagged PHD region ofhPygo2 (Gal-4-hPygo2-2). This result was 
consistent with the design of the antigen which did not include the PHD region. The 
Hausenpfeffer antiserum, designed to interact with amino acids 74-312 ofhPygo2, 
strongly recognized hPygo2 mutants that were truncated at amino acid number 95 (Gal-4-
hPygo2-4, Gal-4-hPygo2-5). This result indicated that the antiserum strongly interacts 
with a region ofhPygo2 containing amino acids 74-95. Expression of the Gal-4-hPygo2 
constructs was confirmed by immunoblotting for the Gal-4 epitope (Figure 3.5 c), using 
an antibody against the Gal-4 protein. The Gal-4 antibody detected all transfected Gal-4 
tagged hPygo2 fusion proteins including the PHD region ofhPygo2 (Gal-4-hPygo2-2), 
confirming that this tagged hPygo2 protein was indeed present in the HeLa cell lysate. 
The Hausenpfeffer antibody was also tested for its ability to interact with endogenous 
hPygo2 protein by western analysis of total whole cell lysate from cultured breast cancer 
cell lines. Immunoblotting freshly extracted total cell lysate from Bt-474 and MCF-7 
breast carcinoma cells with Hausenpfeffer antiserum showed little or no non-specific 
antibody binding (Figure 3.6), but with strong binding to a band at approximately 
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Figure 3.5 Ability of Hausenpfeffer immune serum to recognize different regions of 
hPygo2. Different regions of hPygo2 fused to Gal-4 and were transiently transfected into 
He La cells. Protein was extracted and analyzed for the expression of the transfected 
constructs. The same amount of protein was loaded onto each gel. (a) Gal-4-hPygo2 
fusion protein constructs that were transfected into HeLa cells. (b) Western analysis of 
Gal-4-hPygo2 constructs using Hausenpfeffer antiserum. (c) Western analysis ofGal-4-
hPygo2 constructs using an anti-Gal-4 antibody. The Gal-4 antibody recognizes all Gal-
4-hPygo2 protein constructs. 
a Gal-4 ~ 
hPygo2 (aa 1-406) 406 
312 
Gal-4-hPygo2-1 
321 
Gal-4-hPygo2-2 
406 
74 312 
Gal-4-hPygo2-3 
95 
Gal-4-hPygo2-4 
38 95 
Gal-4-hPygo2-5 c::-.J 
38 406 
Gal-4-hPygo2-6 
11-NLS · -NHO 
b 
• - Synthetic NLS · -PHO 
!li.... !!.i"' !!.i"' J' !!.i"' !li<o 
~~~~~~~ ~~~~$~ 
... >I- '1- >I- >I- >I- >I-
:X JJJJJJ cgt 
113kDa,.. WEt 
91)> hPygo2 
-
.. 
50,.. 
-
35)> ... _ 
28)> 
c 
!li .... !!.i"' !!.i"' !li ... !!.i"' !li<o 
~~~~~~~~ ~~~~~~ 
:>{ ... >I- '1- >I- '1- >I- >I-
cgt JJJJJJ 
113 kDa,.. WB: 
91,.. Gal-4 
50)> 
-
35)> 
28,.. 
-
-... 
Chapter 3: Results 
51 
Figure 3.6 HausenpfefTer immune serum recognizes endogenous cellular bPygo2. 
Whole cell lysate from Bt-474 and Mcf-7 cells was extrncted and analyzed for the 
endogenous expression ofhPygo2. In vitro transcribed/translated hPygo2 (hPygo2) was 
used as a positive control. A 50 kDa hPygo2 band was detected in both cell lines, with 
little or no non-specific binding. 
Whole 
Cell Lysate 
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50 kDa. This band most likely represented hPygo2 since it co-migrated with in vitro 
transcribed/translated hPygo2 protein used as a positive control. 
These results indicate that the antibodies present in tbe Hausenpfeffer immune 
serum specifically interact with denatured synthetically produced as well as 
endogenously produced hPygo2 protein by western analysis, with little non-specific 
antibody binding. 
3.2 Expressional analysis of bPygo2 in cancer 
3.2.1 Expressional analysis of hPygo2 in various cancer cell lines 
3.2.1.1 Expression of hPygo2 mRNA and protein in various cancer cell lines 
To study the role of hPygo2 in cancer, the expression of its mRNA was 
determined in a variety of cell lines derived from normal and malignant tissues. A 
specific probe against hPygo2 was developed, which excluded conserved regions, and 
was used for northern blot analyses to detect hPygo2 mRNA (Figure 3.7 a). Messages 
were highly expressed in ovarian (Sk-Ov-3, Es-2), cervical (HeLa, CaSki), 
neuroblastoma (Sk-N-Sh), breast cancer cell lines (Bt-474, MCF-7), and normal 
ectocervical (HEC) cells. Alternatively, hPygo2 mRNA expression was very low in 
neuroblastoma (T98G), normal endocervical (HEN) and a "normal" breast (Hs-574) cell 
line. To confirm equal loading and transfer ofRNA the same blot was reprobed for the 
"housekeeping" gene GAPDH. 
To confirm the expression of hPygo2 at the protein level, western analysis was 
performed on total cell lysate that was extracted from the cell lines that were used for the 
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Figure 3.7 Expression of hPygo2 and downstream Wnt components in various 
cancer cell lines. (a) Expression of hPygo2 mRNA determined by northern analysis, 
using a probe that specifically recognizes the hPygo2 message. Loading levels of mRNA 
were assessed by reprobing blots with a probe that specifically recognizes GAPDH 
mRNA. The relative positions of the 28s and 18s ribosomal RNAs are indicated. (b) 
Expression of hPygo2 and 13-catenin protein levels determined by western analysis of 
total cell lysate. In vitro transcribed and translated full length hPygo2 protein (hPygo2) 
was used as a positive control. Loading levels of protein were assessed by reprobing blots 
for 13-Actin. (c) Expression ofPygo binding partner Bcl-9. Total RNA was analyzed by 
RT-PCR using primers specific to Bcl-9. Levels of RNA were standardized by RT -PCR 
analysis for GAPDH. -RT, (negative control), without reverse transcriptase. 
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analysis of hPygo2 mRNA (Figure 3.7 b). In vitro transcribed/translated hPygo2 was 
used as a positive control for hPygo2 protein expression. Tite 50 KDa hPygo2 protein 
was expressed at high levels in the ovarian cancer (Es-2), breast cancer (Bt-474, MCF-7), 
cervical cancer (CaSki), and normal ectocervical cells (HEC). hPygo2 was expressed at 
higher levels compared to the mRNA in T98G cells, and expressed at lower levels 
compared to the mRNA in HeLa and Sk-N-Sh cells. Interestingly, hPygo2 was expressed 
at the highest levels in breast cancer cells (Bt-474, MCF-7) and at very low levels in the 
"normal" breast Hs-574 cells, suggesting that the high level of hPygo2 expression may 
play an important role in the breast tumour cells. Finally, the analysis of endogenous 
hPygo2 mRNA and protein shows that its expression was consistently higher in CaSki, 
Bt-474 andMCF-7 and consistently lower in Hs-574 (Figure 3.7 a, 3.7 b). 
3.2.1.2 Expression of hPygo2 strongly correlates with fl-catenin but not Bcl-9 
Pygopus was proposed to be required for the transcription from Wnt responsive 
genes by an interaction with fl-cateuin mediated through Bcl-9 (Thompson eta/., 2002; 
Kramps el a/. , 2002). Therefore, in an attempt to correlate the expression of known Pygo 
binding partners, (3-catenin protein expression was examined and compared to the 
expression of hPygo2 protein. Examination of P--<:atenin protein expression (Figure 3.7 
b), demonstrated that it very closely resembled that of hPygo2 (Figure 3.7 a) in most of 
the cell lines studied, with (3-catenin expression being the highest in Sk-Ov-3, Es-2, 
HEC, CaSki, T98G, Bt-474 and MCF-7 cells. (3-catenin was expressed at lower levels in 
HeLa and Sk-N-Sh cells. Again, the expression ofp~catenin was lower in the normal Hs-
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574 breast cells compared to the breast cancer cells. This result indicates that the 
expression of[}-catenin strongly correlates with the expression ofhPygo2, and it may be 
related to the co-operative function shared by these two proteins. 
Given that Pygopus interacts with the J}-catenin complex through Bcl-9, the 
relative expression levels of Bcl-9 were assessed by RT -PCR in a variety of cell lines 
(Figure 3.7 c). Bcl-9 mRNA was expressed highly in one cervical (HeLa), two ovarian 
(Sk-Ov-3, Es-2), and two neuroblastoma (T98G, Sk-N-Sh) cell lines, while it was 
expressed at lower levels in all of the other cell lines examined. Surprisingly, there was 
little correlation in the expression ofBcl-9 with the expression ofhPygo2 and 1}-catenin. 
3.2.2 Expressional analysis of bPygo2 in breast cancer 
3.2.2.1 bPygo2 is overexpressed in breast cancer cells 
To identifY a potential requirement in the malignancy of breast cancer, hPygo2 
expression was determined in a variety of cell lines derived from both normal and 
malignant tissues. hPygo2 protein levels were highest in the breast cancer cells Bt-474, 
MCF-7, MDA-MB 23 I and MDA-MB 468, levels were lower in the breast cancer cells 
Hs-578 T, Bt-20 and MDA-MB 157 as well as the normal breast cells Hs-574 and Hs-578 
Bst (Figure 3.8). hPygo2 protein levels were consistent with P-catenin protein expression 
in all cancer cell lines tested, except MDA-MB-231 which showed reduced J}-catenin 
and higher levels of hPygo2, as well as the normal breast cell lines Hs-574 and Hs-578 
Bst, which showed higher levels of[}-catenin than hPygo2 (Figure 3.8 a). Therefore, this 
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Figure 3.8 Expression of bPygo2 and downstream Wnt proteins in various breast 
cancer cell lines. Expression of: hPygo2, ~tenin and Cyclin Dl by western blot 
analysis of total cell lysate of the various breast cancer cell lines. In vitro transcribed and 
translated full length hPygo2 protein (hPygo2) was used as a positive control. Loading 
levels of protein were assessed by reprobing for 13-Actin. 
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result supports my hypothesis that the upregulation ofhPygo2 may play an important role 
in breast cancer. 
Finally, the average expression of the cell cycle regulatory protein and Wnt target 
gene, Cyclin D I was also examined in the breast cancer cell lines by western analysis 
(Figure 3.8 a). Cyclin Dl protein was expressed at the highest levels in the normal breast 
cell lines Hs-574, Cyclin Dl was also highly expressed in Bt-474 and MCF-7 malignant 
breast cell lines. Surprisingly, there was little correlation ofCyclin Dl with hPygo2 and 
~--atenin. 
3.2.2.2 bPygol and Bcl-9 expression does not correlate with bPygo2 in breast cancer 
cells 
The interaction ofPygo proteins with ~-catenin was shown to be mediated by 
Legless/Bcl-9 (Thompson eta/., 2002; Kramps eta/., 2002). Therefore, I assessed the 
relative expression levels of hPygol, hPygo2 and Bc/-9 in the breast cancer cell lines 
examined by RT -PCR (Figure 3.9). hPygo2 expression was highest in the breast cancer 
cells Bt-20, Bt-474, MCF-7, MDA-Ma 157, MDA-MB 231 and MDA-MB 468. hPygo2 
was expressed at lower levels in Hs-578 T and the normal cells Hs-574 and Hs-578. 
hPygol expression was highest in Hs-574 and Hs-578 normal breast cells and MCF-7, 
MDA-MB-157 and MDA-MB-231 breast cancer cells, while Bc/-9 expression was 
highest in MDA-MB-157 and MDA-MB-231 breast cancer cells. My results demonstrate 
an upregulation of hPygo2 in 6 of the 7 breast cancer cell lines analyzed. This trend was 
not observed with hPygo I, nor Bcl-9. These results suggest that a functional role of 
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Figure 3.9 Expression of human Pygo and Bcl-9 RNAs in breast cancer cell lines. 
Expression of hPygol, hPygo2 and Bc/-9 was analyzed by RT-PCR in breast cancer cell 
lines. Levels of RNA were standardized by RT-PCR analysis for GAPDH. -RT, negative 
control, without reverse transcriptase. 
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bPygo2 in breast cancer may not require its interaction witb tbe ~tenin transcription 
complex tbrougb Bcl-9. 
3.2.2.3 ~catenin and bPygo2 do not co-localize in MCF-7 and Bt-474 cells 
Since the expression ofhPygo2 in breast cancer cell lines correlated witb the 
expression of 13-catenin. It is possible, however, tbat the J3--catenin in these cells 
localizes to a different subcellular compartment than hPygo2. To address this possibility, 
I used indirect immunofluorescence and confocal microscopy to determine the 
subcellular localization of hPygo2 and 13--<:atenin in the normal and malignant breast cell 
lines (Figure 3.1 0). N. a negative control, preimmune serum was used at the same 
dilution as the hPygo2 immune serum, and showed no significant staining. Endogenous 
hPygo2 protein was predominantly localized to the nuclei of both breast cancer cell lines 
that I analyzed (Bt-474 and MCF-7) but to the cytoplasm and weakly to tbe nuclei of the 
normal breast cell line (Hs-574). Unlike hPygo2, the majority of 13--<:atenin was 
associated with the plasma membrane of the normal and cancer cell lines. Some weak 
perinuclear staining of hPygo2 and 13--<:atenin was observed in all cell lines, which may 
indicate a possible hPygo2 and 13-catenin interaction. These observations indicate that 
the majority of hPygo2 and 13--<:atenin were localized to different compartments in the 
breast cancer cells. 
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Figure 3.10 Expression and subcellular localization ofhPygo2 and JH:atenin in 
breast cell lines. The expression ofhPygo2 (green) and j3-catenin (red) were determined 
in normal breast (Hs-574) cells and malignant breast cancer (Bt-474, Mcf-7) cells using 
immunoflourescence and confocal microscopy. Preimmune serum was used at the same 
dilution as hPygo2 immune serum for a negative control. (Magnification= 200X) 
Hs-574 Bt-474 Mcf-7 
Preimmune Preimmune Preimmune 
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3.2.2.4 hPygo2 is expressed in malignant breast tumours 
The expression of hPygo2 in archived surgical breast tumour specimens was 
determined by immunohistochemical analysis. I obtained 22 archived breast tumour 
sections, most of which were invasive ductal carcinomas, and I normal breast section and 
stained them for hPygo2 protein (Figure 3.11). Tumor cells were differentiated from 
normal cells based on irregularities in cell morphology (Kumar eta/., 2003) and were 
examined by a clinical pathologist (Dr. D. Robb). In 14 (64%) of tumours, there was 
staining ofhPygo2 in malignant cells, but not in the surrounding non-tumour cells. Of the 
14 positively stained specimens 6 (43%) had distinct nuclear and cytoplasmic hPygo2 
staining (Figure 3.10 d), whereas the remaining 8 (57%) tumours had only cytoplasmic 
hPygo2 staining (Figure 3.10 b, c). hPygo2 could not be detected in a normal breast tissue 
section (Figure 3.10 a). I also obtained 41ymph node sections from breast tumour patients. 
Two out of four contained metastatic tumour cells which stained positive for hPygo2 in 
the nucleus and cytoplasm, the remaining two did not contain tumour cells and did not 
stain with hPygo2. Thus, the expression ofhPygo2 in the malignant cells of these 
tumours confirms the results found in established breast cancer cell lines and further 
supports the hypothesis that hPygo2 may play an important role in breast cancer. 
3.3 Functional Analysis of bPygo2 
3.3.1 Design of an antisense oligonucleotide capable of hPygo2 knockdown 
It is possible that full length antisense constructs cause non-specific antisense 
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Figure 3.11 Immunohistochemical analysis of hPygo2 in breast tumours. (a) Normal 
breast tissue negatively stained for hPygo2 (brown). (b-d) Infiltrating ductal carcinomas 
stained with hPygo2 immune serum used at the same dilution which the pre· immune 
serum showed no staining. (b)Weak cytoplasmic hPygo2 staining, (c) strong cytoplasmic 
hPygo2 staining, (d) Strong nuclear and moderate cytoplasmic hPygo2 staining. Tumour 
sections were counterstained with hematoxylin (blue). Scale= I 00 micrometers. 
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effects in cell culture by fonning double stranded RNA or by containing G-quartet 
sequences (Burgess eta/., 1995). To more specifically target the expression ofhPygo2, I 
therefore designed smaller antisense molecules avoiding sequences that may cause non-
specific effects. I designed ten antisense ONs that bind to non-conserved regions of the 
hPygo2 mRNA (Figure 3.12), the relative positions to which they bind the hPygo2 eDNA 
are shown in Figure 3.12 a. In order to detennine which ON would be useful to knock 
down the expression of hPygo2, all ONs were first tested by transfecting them into HeLa 
cells. Twenty four hours after transfection, the relative levels of hPygo2 mRNA was 
detennined by RT-PCR analysis (Figure 3.12 b). A number ofONs reduced the levels of 
hPygo2 rnRNA (ON #3, 5, 8 and I 0), compared to the transfection reagent control 
(Oiigofectarnine) and an ON designed against Xenopus Pygopus 2 (Non-specific oligo). 
Spot densitometry was perfonned and expression of hPygo2 was normalized to the 
expression of the "housekeeping" gene GAPDH. Since ON #5 was found to have the 
greatest ability to knock down the expression of hPygo2 mRNA, it was therefore used in 
subsequent experiments. 
3.3.2 bPygo2 is required for tbe growth of BeLa cervical cancer cells by specific 
knockdown of bPygo2 using antisense ON 
A single oligonucleotide (ON#5, hereon referred to as a-hpy2), which had the 
greatest ability to knock down hPygo2 mRNA expression, was chosen for further 
analysis in HeLa cells. a-hpy2 was transfected along with two control ON, one 
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Figure 3.12 Identification of an antisense oligonucleotide capable of knocking down 
hPygo2 expression. (a) Antisense oligonucleotides were designed against the full 
hPygo2 eDNA sequence, avoiding conserved sequences such as the NHD and PHD 
domains. (b) Antisense oligonucleotides were transfected into HeLa cells at a 
concentration of250nM. RNA was extracted 24 hours later and RT-PCR analysis was 
performed to access the relative knockdown of hPygo2 RNA levels. Densitometry was 
performed, standardizing the relative hPygo21eve1s to the relative GAPDH levels. RT-, 
(negative control), without reverse transcriptase. 
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complementary to Xenopus Pygopu.• 2 (Non-specific) and another ON complementary to 
the u-hpy2 ON with a 4 base-pair sequence substitution (Mismatch). Knock down of 
hPygo2 using the u-hpy2 ON, was accompanied by a significant decrease in cell numbers 
at 48 and 72 hours after transfection compared to reagent alone (Oiigofectamine) and the 
control ON (Figure 3.13 a). Most of the reduction in cell growth occurred at 48 hours 
after transfection, while cell number doubled by 72 hours after transfection, most likely 
due to the normal proliferation ofuntransfected cells. In order to confirm the knockdown 
of hPygo2 mRNA and protein by the u-hpy2 ON, RT -PCR as well as western analysis 
were used (Figure 3.13 b, c). Specific knockdown ofhPygo2 mRNA expression was 
achieved 24hrs after transfection of u-hpy2 compared to the control ON, without 
affecting the expression of the alternate, but related, Pygo family member hPygol (Figure 
3.13 b). The introduction of u-hpy2 into He La cells also resulted in a knock down of 
endogenous hPygo2 protein 48 hours after transfection with tbe u-hpy2 ON (Figure 3.13 
c). These results suggest that specific knockdown of hPygo2, but not hPygo I results in a 
decrease in cell numbers of exponentially growing HeLa cells. 
3.3.3 bPygo2 is required for the growth of MCF-7 and MDA-MB-468 breast cancer 
cells 
Since I have shown that hPygo2 mRNA and protein are expressed at relatively 
high levels in breast cancer cells compared to normal breast cell lines (Figure 3.8, 3.9), I 
hypothesized that the high levels of expression ofhPygo2 in breast cancer cells may be 
required for their growth. 
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Figure 3.13 Knockdown of endogenous bPygo2 using antisense ON in BeLa cervical 
cancer cells. Reagent control (Oiigofectamine), antisense Xenopus Pygopus2 (non-
specific), and four base mismatch (mismatch) controls are indicated. (a) Knockdown of 
hPygo2 by antisense ON results in a decrease ofHeLa cell numbers 48 and 72 hours after 
transfection. Cell number was assayed by direct counting with a hemacytometer using 
trypan blue exclusion. (b) RT-PCR analysis showing specific knockdown of hPygo2 
mRNA without affecting expression of the related Pygo family member, hPygo/. RT-, 
(negative control), without reverse transcriptase. (c) Western blot analysis showing 
knockdown of endogenous hPygo2 protein. Levels of eDNA and protein were 
standarrnzed using GAPDH and 13-Actin. Experiments were performed in triplicate. 
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Transfection of the u-hpy2 ON into MCF-7 cells resulted in a considerable 
reduction of cell numbers (Figure 3.14 a) 48 and 72 hours after transfection with the 
hPygo2-specific u-hpy2 ON, compared to the cells transfected with the NS and MM 
control ONs. At 72 hours after transfection, cell numbers were reduced to 52%, compared 
to 93% with the NS control or 83% for the MM control. The reduction in cell numbers 
was preceded by a significant downregulation ofhPygo2 protein 48 hours after 
transfection, compared to the non-specific and mismatch control ONs while 
~tenin levels remained unaltered (Figure 3.14 b). Further analysis of the Wnt target 
gene and cell cycle regulatory protein Cyclin Dl (Figure 3.14 b), showed that its levels 
were decreased after transfection of the u-hpy2 oligonucleotide suggesting that the 
reduction ofMCF-7 cell number may be due to a reduction of cell growth due to cell 
cycle arrest. 
Similarly, transfection of the breast cancer cell line, MDA-MB-468 with the 
hPygo2 specific ON and control ONs resulted in a significant reduction in cell growth 72 
hours post-transfection. Cell numbers were reduced to less than 50% of controls after 
transfection of the u -hpy2 ON (Figure 3.15 a). hPygo2 protein levels, and to a lesser 
extent j3--;;atenin, were found to be reduced 72 hours after transfection, (Figure 3.15 b). 
3.3.4 jl-eatenin is not required for growth of MCF-7, nor MDA-MB-468 cells 
It was previously shown that MCF-7 cells exhibit Wnt dependent transcription 
and expression of the Wnt target gene, Cyclin D1 (Lin eta/., 2000). Therefore, to confirm 
the involvement of hPygo2 in the canonical Wnt pathway in these cells, I analyzed the 
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Figure 3.14 Knockdown of hPygo2 in Mcf-7 breast cancer cells using antisense ONs. 
Reagent control (Oligofectamine), antisense Xenopus Pygopus2 (non-specific), and four 
base mismatch (mismatch) controls are indicated. Cells were counted with a 
hemacytometer using trypan blue exclusion (a) Growth ofMcf-7 cells 48 and 72 hours 
after initial treatment with antisense ON. Growth is given as the% control transfected 
with transfection reagent alone. (b) Western analysis ofhPygo2, Cyclin Dl and 
~--catenin 48 hours after hPygo2 knockdown by antisense ON. Results indicated are 
based on three experiments performed in triplicate. 
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Figure 3.15 Knockdown of bPygo2 and 11-catenin in MDA-MB 468 cells using 
antisense ONs and siRNA. Reagent control (Oligofectamine), antisense Xenopus 
Pygopus2 (non-specific), and four base mismatch (mismatch) control ONs, along with 
Non-specific control siRNA and 13---<:atenin siRNA are indicated. (a) MDA-MB-468 cell 
growth was assayed at 72 hrs after transfection. (b) Western analysis ofhPygo2 and 
j3--catenin 72 bours after knockdown ofhPygo2 and 13---<:atenin. Protein levels were 
standardized by reprobing blots with 13-Actin. Results indicated are based on three 
experiments performed in triplicate. 
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requirement ofp"""atenin for cell growth in MCF-7 cells by knocking down its 
expression with commercially available siRNA. Since p"""atenin and hPygo2 proteins 
were expressed at high levels in these cells, I hypothesized that growth would be reduced 
following knockdown ofp-Catenin, as was the case for the knockdown ofhPygo2. 
Surprisingly, the depletion ofP-Catenin, was not accompanied by a reduction in 
cell numbers when compared to non-specific siRNA controls 72 hours after transfection 
(Figure 3.16 a). Knockdown of approximately I 00% of Jl~tenin protein levels with 
~atenin siRNA was confirmed by western analysis (Figure 3.16 b). Expression levels 
of hPygo2 and Cyclin D I remained unchanged after ~atenin knockdown when 
compared to reagent alone (Oligofectamine) or a non-specific siRNA (Figure 3.16 b). 
Thus, Jl"""atenin is not required for cell growth, nor for the expression of the Wnt target 
gene Cyclin Dl in MCF-7 cells. 
The knockdown of P~tenin in MDA-MB-468 cells similarly showed no 
reduction in cell numbers 72 hours after transfection compared to the reagent and non-
specific controls (Figure 3.15 a). A reduction in P~tenin protein levels was confirmed 
by immunoblotting siRNA treated MDA-MB-468 cell lysate harvested 72 hours post-
transfection (Figure 3.15 b). 
The lack of requirement for P~tenin in the growth of MCF-7 cells is consistent 
with our observation that it is predominantly localized to the cytoplasm and membrane 
compartments ofMCF-7 and to the membrane compartment ofBt-474 cells (Figure 3.10) 
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Figure 3.16 Knockdown of P-catenin in Mcf-7 cells using RNAi. Reagent control 
(Oligofectarnine) and non-specific siRNA controls are indicated. (a) Growth ofMcf-7 
cells 72 hours after initial treatment with 13-catenin siRNA. (b) Western analysis of 
hPygo2, Cyclin D I and 13-Catenin 48 hours after 13-catenin knockdown by RNAi. Protein 
levels were standardized by reprobing blots with 13-Actin. Results indicated are based on 
three experiments performed in triplicate. 
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and therefore, is not present in a transcriptionally active Wnt complex to promote cell 
growth. 
3.3.5 hPygol but not hPygo2 can induce the activation ofWnt-dependent 
transcription 
To directly address the role ofPygopus proteins in the transcription ofWnt target 
genes, I performed transcription assays in MCF-7 cells using the TOPFLASH vector 
(Figure 3.17). TOPFLASH contains multiple TCF/LEF binding sites which control the 
expression of the reporter gene, Luciferase. The amount ofLuciferase protein transcribed 
and translated can then be measured with a luminometer. As a positive control, a 
constitutively active mutant form ofl3-catenin (S37A) was used which contained a 
missense mutation resulting in an amino acid substitution replacing a Serine residue with 
Alanine. This mutant has been shown to be resistant to proteasomal degradation due to 
lack of phosphorylation at this residue which normally targets 13-catenin for degradation 
(Wu et a!. , 2001). 
Transfection of S37A into MCF-7 cells resulted in an activation ofWnt dependent 
transcription greater than three-fold, while co-transfection ofhPygo2 or Bcl-9 did not 
show an activation of Wnt dependent transcription above this level. In fact, transfection 
ofhPygo2 and S37A resulted in a slight decrease ofWnt dependent transcription. In 
contrast, co-transfection ofhPygol and S37A resulted in an approximate 9 fold increase 
in the Luciferase reporter compared to an empty vector control. These results confirm 
that hPygol is likely the Pygo family member that is involved in the transcription ofWnt 
target genes. 
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Figure 3.17 bPygol but uot bPygo2 mediates canonical Wnt signaling transcription 
in Mcf-7 cells. Mcf-7 cells were transiently transfected with molar equivlents of either 
FOPFLASH (Mutant Tcfbinding sites) or TOPFLASH (Tcfbinding sites) Wnt reporter 
luciferase constructs, in conjunction with constitutively active 13-catenin S37A, hPygol, 
hPygo2 or Bcl-9. Relative luciferase units were determined and normalized to total 
cellular protein. Means and standard deviations indicated are based on three experiments 
performed in triplicate. (a and b, p < 0.005 (p ~ 0.0025); a and c,p < 0.005 
(p ~ 0.0018)] 
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Chapter 4: Discussion 
Although poorly understood, aberrant Wnt signaling has been implicated in the 
progression of breast cancer (Michaelson and Leder, 2001; Li eta/., 2003; Hatsell eta/., · 
2003; Howe and Brown, 2004) . Therefore, the main objectives of this thesis were to 
evaluate the expression and requirement of the novel Wnt signaling family member, 
hPygo2, in breast cancer. With an antibody raised against non-conserved regions of 
hPygo2, I was able to determine its expression in normal and malignant cell lines and 
tumours. To address a possible functional requirement for hPygo2, I designed antisense 
oligonucleotides that specifically knocked down its expression. Interestingly, my results 
indicate a role for hPygo2 in the growth of breast cancer cells, independent ofj3-catenin. 
This finding may help provide insight into novel hPygo2 functions. These results also 
suggest that hPygo2 may be a more suitable therapeutic target than 13--catenin for tbe 
treatment of breast cancer. 
4.1 Development of bPygo2 antisera 
One of the initial objectives of this thesis was to produce an antibody against 
hPygo2. The antibody could then be used as a molecular tool to study the expression of 
hPygo2. In chapter 3.1 of the results section, I have shown the successful production and 
characterization of an antibody that specifically recognizes hPygo2. In general, all 
antibodies were able to bind specifically to the native hPygo2 protein compared to the 
preimmune sera used as a negative control as shown by immunoprecipitation and by 
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immunoflourescence. The preimmune sera, however, was not used as a negative control 
for the western blots that were performed. This would have been a good negative control 
to confinn the specificity of the antibodies used to identiry denatured hPygo2 protein. 
The Hausenpfeffer immune serum was raised to avoid cross reactivity with 
conserved protein motifs present in the Pygo2 protein which may be present in other 
cellular proteins. For example, the PHD domain was proposed to mediate protein-protein 
interactions (Aasland eta/., 1995), and has since been shown to be present in many other 
proteins. It was important to avoid raising antibodies that would cross react with this 
domain since I wanted them to specifically interact with hPygo2. Therefore, I designed 
the Pygopus protein antigen to exclude all conserved amino acid sequences. 
4.2 Antisense oligonucleotide and siRNA design 
The ability of antisense ONs to inhibit protein production was first discovered in 
1978, when a short 13 nucleotide antisense ON was used to inhibit tbe translation of viral 
proteins and therefore inhibit the replication ofRous sarcoma virus (Stephenson and 
Zamecnik, 1978; Zamecnik and Stephenson, 1978). Since then, the use of antisense ONs 
has become a common method to knock down the expression of a protein. This is a 
particularly useful method to specifically target overexpressed gene products that may 
play roles in the malignancy of a given cancer. 
There are a number of potential problems associated with the use of antisense ON 
and a number of considerations must be taken into account in the design and use of 
antisense ON with regard to tbe mRNA structure, ON sequence and modifications. 
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The three dimensional structure resulting from folding and post transcriptional 
modification of an mRNA is complex. Therefore, the efficacy of an antisense ON is 
mostly dependent on its accessibility to the target sequence. Complex algorithms are 
useful in predicting efficient antisense ON sequences, but they cannot exactly predict 
how mRNA is folded or arranged in the cell, so effective antisense ON design is typically 
done stochastically. 
When choosing the sequence for an antisense ON, it is important to carefully 
consider the antisense ON sequence. This will have a direct impact on the formation of 
secondary structures within the antisense ON. The less secondary structure that there is 
present the less likely that the ON will interact with itself instead of interacting with its 
target sequence. Other considerations must also be made with regard to the antisense ON 
sequence. For example, it is also important to avoid repeated CG sequences as well as 
GGGG sequences. In eukaryotes the cytosine adjacent to a guanine is usually methylated. 
Therefore, unmethylated CG sequences in vivo can initiate the activation of an immune 
response, as it has been shown that unmethylated CG sequences in mice result in B-cell 
activation and the secretion of antibodies (Krieg eta/. , 1995). Also, antisense ON 
containing GGGG may also result in non-specific effects. For example, it was found that 
antiproliferative effects of antisense ON for c-myb and c-myc in smooth muscle cells was 
caused by a non-antisense mechanism likely due to the presence of a GGGG sequence 
(Burgess eta/., 1995). These examples illustrate the importance of the antisense ON 
sequence chosen for experimentation. 
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Lastly, it is possible to chemically modify ON. This is an important consideration 
to take into account when designing an antisense ON. The halflife of the ON will have 
direct consequences on its efficiency to reduce levels of gene expression. In the cell, the 
nuclease family of enzymes function to degrade DNA molecules. Therefore, many 
antisense ONs that are used today contain modifications that enhance their nuclease 
resistance. Although many modifications of antisense ON exist, one of the most popular 
modification of antisense ON is the replacement of phosphodiester bonds with 
phosphorothioate bonds (Green eta/., 2000). In an antisense ON, phosphorothioate bonds 
greatly enhance the half life of an antisense ON to resist nuclease mediated degradation 
More recently, antisense ON containing 2' -0-methyl groups have been shown to have 
greater stability and higher affinity for target RNA molecules (McKay eta/., 19%). 
Therefore, 2' ..0-methyl modified antisense ON directed against hPygo2 may have 
improved antisense effects compared to phosphorothioate ON used in this study. Indeed, 
the use of antisense ON is an efficient way to down regulate certain gene products in a 
disease state. There are many examples studying the effects of antisense ON and there are 
some antisense ON which have entered clinical trials, such as an antisense ON targeting 
Protein Kinase Ca (McGraw eta/., 1997). 
4.3 Role of hPygo2 in breast cancer 
To date, canonical Wnt signaling has a poorly understood role in breast cancer. 
Wbile J3-catenin has been reported to have nuclear/cytoplasmic staining in 
approximately 60% of breast tumours in two independent studies (Lin eta/., 2000; Ryo et 
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a/., 2001), mutations in Wnt pathway components that activate !3--catenin occur at 
relatively low frequencies (Polakis, 2000; Smalley and Dale, 2001; Giles eta/., 2003). It 
has been suggested that overexpression ofWnt ligands or reduced expression ofWnt 
antagonists may lead to the nuclear stabilization of j}-catenin in mammary 
carcinogenesis (Howe and Brown, 2004 ). The absence of a conclusive answer to this 
apparent discrepancy necessitates an understanding of the true requirement for Wnt and 
!3--catenin nuclear complexes in breast epithelial malignancy. 
My results are the first demonstration of the potential requirement for the protein, 
hPygo2, in cancer. I have shown that hPygo2 protein, which is normally present at lower 
levels in the cytoplasm of normal adult cells, is found at higher levels in the nuclei of 
certain cancer cells, potentially representing a key step in the progression of this disease. 
Nuclear localization ofPygopus is important for its proposed function as a transcriptional 
activator (Thompson eta/., 2002; Kramps eta/., 2002). It is possible that hPygo2 may be 
sequestered in the cytoplasm in normal cells by another cytoplasmic anchoring protein, as 
is the case for the cytoplasmic retention ofl3--<:atenin in the absence of a Wnt sigoal. On 
the other band, when cells are actively dividing, hPygo2 may be recruited to the nucleus, 
to function as a transcriptional regulator thereby activating the expression of genes 
involved in promoting cell cycle progression or repressing genes involved in apoptosis. 
More work is required to address the functional sigoificance ofhPygo2 in normal 
breast cells. This could be done by constructing a nuclear localization deficient hPygo2 
protein, which could be used as "bait" in order to examine cytoplasmic interacting 
proteins. The identification of key cytoplasmic interacting proteins may help to elucidate 
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the role ofhPygo2 in normal breast cells. Also, knockdown ofhPygo2 with antisense ON 
could also be performed in normal breast cells. Tbereby confirming, whether or not, that 
the growth reduction of the breast cancer cell lines examined was specific to a cancer cell 
and not to a normal cell. 
My data also indicate that hPygo2 was required for the growth of mammary 
carcinoma cells (MCF-7, MDA-MB 468) and for the expression of the Wnt target, and 
cell cycle promoting gene Cyclin Dl in Mcf-7 cells. The Cyclin Dl protein is a positive 
regulator of cell cycle and required for G I to S phase transition (Coqueret, 2002; Stacey, 
2003). The increased expression ofCyclin Dl in actively dividing cells promotes cell 
cycle progression by forming a complex with Cyclin Dependent Kinase 4 (CDK4). This 
complex has been shown to increase phosphorylation of the Retinoblastoma protein 
(pRb), therefore promoting cell cycle progression through the Gl phase (Kato eta/., 1993; 
Ewen eta/., 1993). Therefore, the reduction ofCyclin Dl by hPygo2 antisense suggests 
that the cells may be arresting in the G I phase of the cell cycle and may be due to a 
decrease in the phosphorylation of pRb. 
Along with growth reduction and a reduction of Cyclin D 1 protein, hPygo2 
siRNA treatment of MCF-7 cells, resulted in a decrease in the expression ofCyclin A (K. 
Kao, unpublished observations). Cyclin A, which is involved promoting inS phase of the 
cell cycle by binding to CDK 2, thereby activating proteins involved in DNA replication, 
may also result in growth arrest (Yarn eta/. , 2002). It is possible that the reduction in 
Cyclin A, a gene that is not directly regulated by Wnt signaling, is due to a cascade effect 
involving the downregulation of Cyclin D 1. For example, a decrease in the levels of 
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Cyclin D I results in a decrease in E2F transcription factor activity (Johnson, 1995). A 
reduction in the E2F transcription fuctor can then lead to a decrease in the expression of 
Cyclin A (Schulze eta/., 1995). Therefore, the decrease in Cyclin A after hPygo2 siRNA 
treatment may he a secondary effect resulting from the knock down of Cyclin D I. This 
could he addressed by a knockdown ofCyclin Dl with antisense ON or siRNA to 
determine iflevels of Cyclin A are affected. Also, it is possible that hPygo2 may he 
directly or indirectly regulating the transcription of Cyclin A by an undetermined 
mechanism. Therefore, these results suggest that the knockdown ofhPygo2 may he 
resulting in the growth arrest of the cancer cells examined. Although, more work is 
required to confirm that the reduction in cell numbers was not due to apoptosis. 
4.4 bPygo2 and fl-catenin may function independently in breast cancer cells 
Pygo proteins overexpressed in breast cancer may play an additional role than the 
proposed mediation of canonical Wnt signals. This hypothesis is consistent with studies 
demonstrating transcriptional activity of DNA tethered Gai4-Pygo2 fusion proteins 
(Belenkaya eta/., 2002; Townsley eta/., 2004) and ofPygo2 constrocts lacking 
p-catenin binding sequences that are either fused to dominant activating TCF (Thompson, 
2004) or expressed on their own (Lake and Kao, 2003). In fact, a Gai-4-Pygo2 fusion 
protein tethered to a Gal-4 binding site can activate transcription in ovarian cancer cells 
that do not express f3-catenin (K. Kao, unpublished observations). Therefore, hPygo2 
may he recruiting a number of other proteins to activate transcription in the absence of 
!3-catenin, indicating another possible functional role ofhPygo2. Also I have shown that 
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hPygol mediates the Wnt signal through !3--<:atenin, while hPygo2 does not (Figure 3.17). 
These results, therefore, support a model in which human Pygo2 probably acts as a 
transcription factor, by recruiting other proteins in a !3--<:atenin independent manner, and 
that human Pygol, like Drosophila Pygo, is likely dedicated to the Wnt signaling 
pathway through 13--<:atenin. 
In further support of this model, my results demonstrated that the expression 
levels of hPygo2 correlated with the expression of 13--<:atenin but not its only known 
binding partner, Bcl-9. The breast cancer cell line MCF-7, used in this study, was 
previously shown to exhibit Wnt-dependent transcription, Cyclin OJ expression, as well 
as 13--<:atenin/TCF complex forrnation (Lin eta/., 2000). The Wnt-dependent 
transcriptional activity of this cell line has also been compared to a number of other 
breast cancer cell lines, including one that contains a mutation in APC (DU4475) which 
results in constitutive Wnt activation and transcription. Compared to these APC-deficient 
cells, the MCF-7 cells have a relatively low, almost basal level ofWnt activity (van De et 
al., 2001 ), in contradiction to that reported by Lin. My results confirrn those obtained in 
the forrner study (van De et. al., 2001) and it is therefore not surprising that Bcl-9 
expression does not correlate with that of !3--<:atenin and hPygo2. 
These findings, as well as the lack ofBcl-9 expression in MCF-7 cells, supports 
my hypothesis that hPygo2 may have an independent function from !3--<:atenin. IfWnt 
signaling were actively occurring in these cells, which is unlikely, I would have expected 
Bcl-9 to be present to tether Pygo to the 13--<:ateninffCF complex (Kramps et al., 2002). 
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Therefore, I suspect that canonical Wnt signaling may be absent or occur at low levels in 
these cells, given that the expression ofBcl-9 is limiting. 
In further support of my hypothesis, inhibition of J}-catenin by ICAT 
overexpression had no effect on HeLa cell growth (Sek:iya eta/., 2002), consistent with 
my observations using 13--<:atenin siRNA in MCF-7 cells. These data suggest that at least 
in two cancer cell lines, canonical Wnt signaling does not appear to be important for cell 
growth. Indeed, it has been found that hPygo2, but not 13--<:atenin was required for 
survival of at least one other epithelial ovarian cancer cell line, TOV-21 G (K . .Kao, 
Manuscript in preparation). It has also been previously reported a requirement for Pygo2 
in the transcription of the non-Wnt responsive genes in Xenopus embryos (Lake and .Kao, 
2003). These data further imply an additional functional role ofhPygo2, independent of 
J}-catenin. 
The proposed function of Pygo in mediating the remodeling of chromatin may be 
too simplistic, since DNA tethered Pygo shows transcriptional activity (Belenkaya eta/., 
2002; Townsley et at., 2004). It is also well known that the histone acetyltransferase, 
p300/CBP is associated with the j3--<:atenin!TCF complex and likely functions to regulate 
chromatin structure at Wnt promoter sites (Hecht et a/., 2000). In fact, p300/CBP also 
contains a PHD domain which has been shown to he an essential component of the 
acetyltransferase domain ofp300/CBP (Kalkhoven eta/., 2002). Therefore, the 
requirement of the PHD domain ofPygopus as well as its putative chromatin remodeling 
function in the transcription ofWnt target genes seems to be redundant in the 
transcription of Wnt target genes. 
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It has been previously shown that levels of Wnt signaling determined by 
transcription assays showed a strong correlation with the expression ofCyclin Dl in 
breast cancer cells including MCF-7 (Lin eta/., 2000). Because, as I have shown, 
f3-catenin is not required for the expression of Cyclin D I in these cells, the expression of 
Cyclin Dl may not be a true indication of canonical Wnt signaling. This result is 
consistent with immunohistochemical studies of infiltrating ductal carcinomas tbat were 
shown to exhibit a divergence of Cyclin Dl and j3-catenin expression (Lim and Lee, 
2002). Indeed, Cyclin Dl expression has been shown to be required for cell growth and 
is regulated by other non-Wnt dependent proteins in MCF-7 cells, such as estrogen 
receptor (Watts eta/. , 1994) and Peroxisome Proliferator-activated Receptor :y (PPARy) 
(Yin eta/., 2001; Qin eta/., 2003). My results suggest tbat Cyclin Dl may not be strictly 
regulated by J3- catenin in MCF-7 cells, as Cyclin D I is likely regulated by many other 
factors in these cells. 
Reduction ofhPygo2 on the other hand, did result in a decrease ofCyclin DI 
(Figure 3.14), which leads one to question the role ofhPygo2 in its expression. Since 
Cyclin Dl is a known Wnt target gene, it is possible that hPygo2 may directly regulate its 
expression independently ofJ3-Catenin. Since Cyclin Dl expression is regulated by 
factors (estrogen receptor and PPARy) other than j3-catenin, I hypothesize that hPygo2 
might be either directly or indirectly involved in the regulation of these factors in the 
transcriptional regulation of the Cyclin Dl gene. Futhennore, hPygo2 may regulate the 
turnover ofCyclin DI by a post translational mechanism independent of transcriptional 
regulation. 
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4.5 Conclusions 
In conclusion, I have confirmed my hypothesis that the overexpression of hPygo2 
may contribute to the growth of breast cancer cells, which I have demonstrated through 
expressional knockdown of hPygo2. Wnt-dependent transcription was shown to require 
Pygopus in colorectal cancer cells (Thompson eta/., 2002), and, while not assayed, 
growth of these cells is predicted to be inhibited by Pygo knockdown consistent with that 
shown for j3--<:atenin (Rob eta/., 2001; Sekiya eta/., 2002; Verma eta/., 2003). Not all 
cancers likely involve deregulation of the j3--<:ateninlhPygo2 complex. Divergence of 
these components, however, suggests the potential for a more global involvement of Pygo 
proteins than j3--<:atenin in cancer. This would make Pygo a more suitable therapeutic 
target, and necessitate a greater understanding ofPygo functional protein associations. 
4.6 Future directions 
The expression ofPygopus in malignant cell lines and tumours, suggests that 
there may be a correlation between hPygo2 expression and disease. To confirm this 
finding, a study utilizing a larger patient population would be needed. Factors such as 
patient survival, disease-free survival as well as information on how the patient was 
treated for their disease could be correlated with hPygo2 expression to determine if 
hPygo2 could be used as a prognostic marker. 
There has been no work demonstrating the transcriptional regulation ofhPygo2. 
This is an important question to consider since hPygo2 expression was upregulated in 
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cancer. Is the overexpression ofhPygo2 in breast cancer due to its constitutive 
transcriptional up-regulation? To address this question, I analyzed the promoter region of 
hPygo2 and found that there are consensus sites for the transcription factor E2F (Data not 
shown). Many cancers downregulate the pRB pathway resulting in E2F activation and 
the transcription of genes involved in cell cycle progression (Yamasaki, 2003), this may 
partially explain the high levels of expression of Pygpus in cancer. Experiments to further 
explore this finding could include cloning the promoter region ofhPygo2 into a 
promoter-less expression vector to regulate the expression of a reporter gene such as 
Luciferase. To further characterize a possible transcription factor-DNA interaction, 
chromatin immunoprecipitation could be used, alone or in conjunction with 
electrophoretic mobility shift assay to determine which regions of the promoter that the 
hypothesized transcription factors bind. A functional demonstration of the transcriptional 
regulation ofhPygo2 by E2F could he performed by knockdown or overexpression of 
E2F followed by western blotting for hPygo2 to monitor protein expression changes. 
Legless/Bcl-9 is hypothesized to interact with Pygopus in Drosophila (Kramps et 
a/., 2002), and I have shown that hPygol, but not hPygo2, is required for Wnt dependent 
transcription. It would therefore be interesting to study the interaction of Bcl-9 with both 
human Pygo family members. Since I have shown that Bcl-9 does not activate Wnt 
dependent transcription, I hypothesize that its interaction with Pygopus may he restricted 
to hPygo2. This could be easily confirmed by co-immunoprecipitation experiments to 
identifY the protein interactions. 
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Finally, in order to directly address my hypothesis that hPygo2 may act 
independently of f3--<:atenin, proteomics could be used as a tool to identify hPygo2 
interacting proteins. Using the antibodies that I have produced to immunoprecipitate 
hPygo2 from MCF-7 cells followed by proteomic analysis would be a great method to 
identify proteins that interact with bPygo2. Candidate hPygo2 interacting proteins would 
have to be further confirmed to interact, and analyzed to determine the functional 
significance of the protein-protein interaction. 
Identification of known proteins that interact with hPygo2 could be identified by 
immunoprecipitation of hPygo2 from cells followed by separation of proteins by high 
resolution, twn dimensional gel electrophoresis. Proteins spots stained with Coomassie 
Blue could then be isolated and digested with a specific protease, such as trypsin. Trypsin 
digestion yields a peptide "fingerprint" which contains specific peptide fragments of a 
larger protein. The peptide "fingerprint" of the mass/charge ratios of the peptide 
fragments could then be determined by matrix-assisted laser desorption/ionization time of 
flight, also known as MALDI-TOF mass spectroscopy. Database analysis of the 
mass/charge ratios of peptide fragments could then be used to identify the interacting 
protein. 
Identification of unknown proteins that interact with hPygo2 could be identified 
in the same way as stated above, except that tandem mass spectroscopy could be used. 
Tandem mass spectroscopy ultimately can lead to the determination of amino acid 
sequence present within the mixture of hPygo2 interacting proteins. Amino acid 
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sequences could then be used to identifY predicted proteins present within the human 
genome and hence, identifY unknown predicted proteins that internet with hPygo2. 
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